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Endothelial cells (ECs) line the inner wall of blood vessels in every organ and regulate 
the flow of nutrient substances, diverse biologically active molecules, and the blood cells 
themselves. The gate-keeping role of endothelium is influenced by the presence of membrane-
bound receptors for numerous molecules including proteins (e.g. growth factors, procoagulant 
and anticoagulant proteins), lipid transporting particles (e.g. low-density lipoprotein [LDL]), 
metabolites (e.g. nitric oxide and serotonin), and hormones (e.g. endothelin-1), as well as 
through specific junctional proteins that govern cell-cell and cell-matrix interactions. Thus, 
the endothelium represents a dynamic, heterogeneous structure, a widely disseminated organ 
that possesses vital secretory, synthetic, metabolic, and immunologic functions. 
The endothelial cells are highly heterogeneous among and within the tissues. 
Variations in the morphology of the capillaries in different organs have long been recognized 
and differences in function have been recently postulated. For example, the brain and retina 
are lined by continuous endothelial cells (ECs) connected by tight junctions that help to 
maintain the blood-brain barrier. The liver, spleen, and the bone marrow sinusoids are lined 
by discontinuous ECs that allow cellular trafficking between intercellular gaps, while the 
intestinal villi, endocrine glands, and kidneys are lined by fenestrated ECs that facilitate 
selective permeability required for efficient absorption, secretion, and filtering (Dejana 1996). 
ECs from diverse tissues are also heterogeneous with respect to their surface phenotype and 
protein expression. For example, von Willebrand factor (vWF), used commonly as a marker 
for ECs, is not expressed uniformly in all types of vessels (Kumar et al. 1987), the expression 
of tissue type plasminogen activator is limited in vivo to approximately 3% of vascular ECs 
(Levin et el. 1997), and the constitutive expression of u-PA is reportedly confined to renal 
ECs (Wojta et al 1989; Louise et al 1994). The induction of Tissue Factor (TF) after infusion 
of cytokines or endotoxin is similarly restricted to specific vessels (Drake et al. 1993).  
One of the clearest examples for EC heterogeneity lies in the expression of homing 
receptors involved in cell trafficking. In the mouse, Lu-ECAM-1 (lung-specific EC adhesion 
molecule) is exclusively expressed by pulmonary post capillary ECs and some splenic venules 
(Zhu et al. 1991), whereas Mad-CAM-1 (mucosal addressin cell adhesion molecule-1) is 
expressed primarily on high endothelial venules in Payer’s patches of the small intestine 
(Butcher et al. 1996).  Microvascular ECs derived from the bone marrow bind to 
megakaryocytes and CD34+ progenitor cells, and constitutively secrete hematopoietic 
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stimulating factors such as Kit-ligand, granulocyte colony-stimulating factor, granulocyte-
macrophage colony-stimulating factor, and interleukin-6 (IL-6), that contribute to control cell 
trafficking, proliferation, and hematopoietic lineage-specific differentiation (Rafii et al. 1995). 
I.1 Endothelial progenitor cells (EPCs) 
 Mature endothelial cells are terminally differentiated cells with a low proliferative 
potential, and their capacity to substitute damaged endothelium is limited. Therefore, the 
endothelial repair may need the support from other cell types. Accumulating evidence in the 
last years indicates that the peripheral blood of mammalian organisms contains a unique 
subtype of circulating, bone marrow-derived cells with properties similar to those of 
embryonal angioblasts (Asahara et al. 1997). These cells, which have the potential to 
proliferate and differentiate into mature endothelial cells, were termed endothelial progenitor 
cells (EPCs). Recent studies in animals and humans suggest the ability of EPCs to ameliorate 
the function of ischemic organs, apparently indicated by both induction and modulation of 
vasculogenesis and angiogenesis in areas with reduced oxygen supply and/or by stimulating 
reendothelialization of injured blood vessels (Hristov et al. 2003). EPCs may have different 
origins, depending on the time of isolation and the source of isolation. There are bone 
marrow-derived EPCs characterized by markers like CD34+, CD133+, and vascular 
endothelial growth factor receptor-2 (VEGFR-2) known as KDR or FLK-1 (Peichev et al. 
2000; Gehling et al. 2000). CD 34 is the main marker for progenitor cells; it is a cell surface 
glycoprotein involved in cell-cell adhesion and mediates the attachment of stem cells to bone 
marrow extracellular matrix or directly to stromal cells. CD133 (termed originally AC133) is 
a 120 kDa transmembrane polypeptide, expressed on hematopoietic stem and progenitor cells 
from human bone marrow, fetal liver and peripheral blood (Yin et al. 1997). A possible mix 
of both, early progenitor and endothelial phenotype is a CD133+/ CD34+/ VEGFR-2+ cell, 
which does not express vascular endothelial (VE) cadherin and von Willebrand factor (vWF). 
Cells with these characteristics are localized predominantly in the bone marrow (Quirici et al. 
2001). In the peripheral circulation of adults, more EPCs are found which have lost CD133, 
but are positive for CD34 and VEGFR-2. Mature ECs show a high expression of VEGFR-2, 
VE-cadherin, and von Willebrand factor. It is unclear at which time point the EPCs begin to 
lose their CD133, during the transmigration from bone marrow into the systemic circulation 
or later during their circulation. Circulating EPCs express with different intensity a variety of 
markers, typical for the endothelial lineage. These markers include platelet endothelial cell 
adhesion molecule-1 (PECAM-1, CD31), CD146, VE-cadherin, vWF, endothelial NO 
synthase, and, after stimulation, E-selectin (Quirici et al. 2002; Kaushal et al. 2001). The 
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release of EPCs from the bone marrow is regulated by a variety of growth factors, enzymes, 
ligands, and surface receptors. Activation of matrix metalloproteinase-9 (MMP-9), which 
promotes the transformation of membrane bound Kit ligand to a soluble Kit ligand and the 
subsequent migration of c-Kit-positive stem and progenitor cells to the vascular zone of the 
bone marrow microenvironment are initials steps in this process (Heissig et al. 2002). 
I.2. Embryonic endothelial progenitor cells (eEPCs) 
 EPCs first appear at the early stages of vasculogenesis and angiogenesis during 
embryonic vascular development (embryonic EPCs or eEPCs). Hatzopoulos et al 1998, were 
the first to establish a method for isolation of cells from murine embryos at E7.5, with 
characteristic properties of endothelial progenitors by using a combination of an appropriate 
stromal cell layer and growth conditions. The isolated embryonic cells displayed unlimited 
stem-cell-like growth potential and a stable phenotype in culture. Analyses on the RNA level 
revealed that these cells express the endothelial specific genes Tie-2 and Thrombomodulin 
(TM), as well as the early mesodermal marker Fgf-3. These cells possess the potential for in 
vitro differentiation with retinoic acid and cAMP treatment, leading to the induction of a set 
of genes, including Flk-1, vWF, TM, GATA-4, and GATA-6. Electron microscopy reveals 
that in vitro differentiation is associated with increased amounts of rER and Golgi, and a 
dramatic increase in secretory vesicles packed with vWF. When these embryonic cells are 
cultured in Matrigel, they assume the characteristic endothelial cobblestone morphology and 
form tubes (Hatzopoulos et al 1998). Injection into chicken embryos shows incorporation of 
the cells in the endocardium and the brain vasculature. The expression of TM, Tie-2, GATA-4 
and GATA-6 suggests that the eEPCs are derived from the proximal lateral mesoderm, where 
the pre-endocardial tubes form. These eEPC are a powerful tool for analyzing regulation of 
early vascular development. The circulating eEPCs appear to have a specific homing into 
tumor microvasculature, extravasate into the interstitium, form multicellular clusters, and 
incorporate into functional vascular networks. Expression analysis and in vivo blocking 
experiments provide evidence that the initial cell arrest of eEPC homing is mediated by E- and 
P-selectins and by P-selectin glycoprotein ligand 1 (Vajkoczy et al. 2003). Even more, 
genetically manipulated eEPCs armed with suicide genes like the yeast cytosine deaminase 
(CD) fused to uracil phosphoribosyl transferase (UPRT) converting the harmless 5-
fluorocytosine (5-FC) to the cytotoxic compound 5-fluorouracil, have been used successfully 
to reduce lung metastases (Wei et al. 2004). 
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I.3. Endothelium and the MAPK signaling pathways 
 ECs are actively responding to a large variety of stimuli incoming from the 
surrounding environment. Such a response needs to be quick, specific, spatially and 
temporary coordinated with the signals received from other cells or tissues, in order to induce 
an appropriate response to the challenge. The intracellular signaling includes the mitogen-
activated protein kinase (MAPK) signaling cascades. Activation of MAPK represents an early 
mechanism by which the cells transduce intracellular signals in response to extracellular 
stimuli. MAPK are activated via phosphorylation catalysed by distinct upstream kinases on 
both tyrosine and threonine residues within their catalytic domains. Since MAPK activations 
are vital for the cells, a high degree of homology exists between different species. The core 
component of a MAPK module is a set of three sequentially acting kinases. In the ECs, like in 
most mammalian cell types three MAPK modules can be distinguished: ERK (extracellular 
signal-regulated kinase), JNK (c-Jun N-terminal kinase) and the p38/MAPK pathways. These 
pathways regulate a variety of responses including cells growth, differentiation, and 
adaptation to the environment as well as apoptosis (Robinson 1997; Ip 1998). The MAPKs 
also control numerous regulatory processes during development and homeostasis (Schaeffer et 
al. 1999; Stronach et al. 1999).  
The mammalian ERK module, also known as the classic mitogen cascade, consists of 
the serine/threonine kinase Raf, MEK, and ERK. For MEK and ERK, two isoforms have been 
described, while three isoforms for Raf, A-, B-, and C- are known. The Raf/MEK/ERK 
signaling cascade becomes strongly activated by mitogenic stimuli such as growth factors.  
 Binding of a growth factor [e.g. epidermal growth factor (EGF)] to the corresponding 
receptor tyrosine kinase (RTK) leads to its oligomerisation and subsequent 
autophosphorylation. Phosphorylated tyrosines on the intracellular part of the receptor serve 
as docking sites for the SH2-domain (Src homology) of adapter protein Grb2, which itself 
binds via the SH3-domain to the proline rich motif of the GDP-GTP exchange factor Sos (son 
of sevenless). Sos interacts with Ras and activates the exchange of GDP to GTP (Bonfini et al. 
1992; Koretzky et al. 1997; Schlessinger et al. 1993). GTP loaded Ras leads to the recruitment 
to the cell membrane of the cytosolic serine/threonine kinase Raf (Rapp et al. 1983; Avruch et 
al. 1994; Stokoe et al. 1994). This translocation results in the activation of the membrane 
associated Raf. Ras-Raf interaction alone is not sufficient to activate Raf completely (Dent et 
al. 1995; Haffner et al. 1995). Important as scaffold proteins for Raf functions are also the 14-
3-3 proteins, which modulate Raf activities (Hagemann et al. 1999).  
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The regulation of Raf is complex involving protein-protein interactions, 
phosphorylation of tyrosine, threonine, and serine residues and cellular relocalisation. 
Activation mediated by multiple kinases like Src, PKC (Protein-kinase C) and PAK (p21 
(Rac/Cdc42)-activated protein kinase) leads to the phosphorylation and positive regulation of 
Raf (Morrison et al. 1997; Kolch et al. 1993). The down regulation of the Raf activity is 
achieved by PKA (protein kinase A) (Graves et al. 1993). 
The first characterised downstream partner of Raf isoenzymes was the MEK kinase 
phosphorylated at Serine 218 and 222 (Macdonald et al. 1993; Papin et al. 1995). Once 
activated, MEK transduces the signals through phosphorylation on T-E-Y motifs in the MAP-
kinases ERK1 (p44) and ERK2 (p42) (Boulton et al. 1991; Thomas et al. 1992). ERK 
phosphorylation increases its catalytic activity, mediates oligomerisation and transmits the 
signals into the nucleus. ERKs are nuclear shuttle kinases and have several described 
substrates in contrast to its upstream activators Raf and MEK. Their target proteins are e.g. 
serine/threonine kinases like 3pK, ribosomal S6 kinase (RSK1p90), RNA-polymerase II, 
phospholipase A2, and several transcription factors like, Elk-1 and c-Jun (Sithanandam et al. 
1996; Blenis et al. 1993; Ludwig et al. 1996; Hill et al. 1995). Expression of constitutively 
active components of the pathway causes cell transformation. All the kinases of the ERK 
pathway participate in tumour formation. It is important to note that decision to proliferate or 
differentiate depends on the length of time that MAPK pathway is activated (Lawlor at al. 
2000).  
 
I.4. Raf family proteins in the MAPK signaling 
 Raf comprises a family of three kinases, A-Raf, B-Raf and Raf-1 (also named C-Raf or 
C-Raf-1). C-Raf is expressed in all cell types and tissues but mostly in striated muscle, 
cerebellum, and fetal brain. A-Raf and B-Raf exhibit a rather restricted distribution. A-Raf is 
mostly expressed in kidneys, ovaries, epididymis and at low levels in other tissues (Storm et 
al.1990). B-Raf is predominantly expressed in neuronal tissue, testes, endothelium and in 
mammalian hematopoietic cells (Eychene et al. 1995). The genes for A-, B-, and C-Raf 
proteins are located on X chromosome at position Xp11.2, chromosome 7p34, on 3p25 




Figure 1-1 Raf family proteins domain structure   
        (From Chong et al. 2001) 
 
B-Raf has an open reading frame of 2.3 kb, A-Raf transcript is 2.6 kb, and C-Raf is 3.4 
kb. Molecular weight of A-Raf is 68 kDa; C-Raf has a calculated molecular weight of 74 kDa 
and B-Raf of 95 kDa. B-Raf has several splice variants, which are specific for the different 
tissues and cell types. For example in mouse brain extracts splice products were detected 
ranging from 65-70 kDa to 95-105 kDa (Moodie et al. 1994). In the PC12 cell line, B-Raf 
proteins were detected either as a single 95 kDa band (Stephens et al. 1992) or as two proteins 
at 67 and 95 kDa (Oshima et al.1991). The three proteins from the Raf family have a similar 
type of organization and high level of homology in between. They consist of three conserved 
regions CR1, CR2, and CR3. In between them there are linker areas. B-Raf shows 52% 
homology to A-Raf and 54% to C-Raf (Sithanandam et al. 1990) (Fig.1-1). The molecules in 
the Raf family contain two functional domains. The amino-terminal regulatory domain 
(containing the conserved regions CR1 and CR2), and the carboxy-terminal kinase domain 
(constituting the third conserved region, CR3) (Daum et al. 1994).  
 Caenorhabditis and Drosophila express a gene similar to mammalian Rafs. In bony 
fish, amphibians and birds only C- and B-Raf isoforms have been identified, but not A-Raf, 
while mammals have all three Raf genes (Calogeraki et al. 1993). 
 
I.4.1. Regulation of Raf activities  
 The process of Raf activation, best analyzed for C-Raf, is still not completely 
understood. It is known to require protein-protein interactions, phosphorylation, and 
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presumably lipid binding (Daum et al. 1994; Slupsky et al. 1998). It was proposed that Raf 
dimerization also might be involved in activation (Luo et al.1996; Masson et al. 1999; Farrar 
et al. 1996). There is increasing evidence that individual Raf isozymes are differentially 
regulated by these factors. 
 
 I.4.1.1. Small G Proteins 
 The small G protein Ras is the direct upstream activator of Raf, which in its GTP-
bound activated form recruits the inactive cytoplasmic Raf to the plasma membrane for 
activation (Slupsky et al. 1998). There are differences in the ability of the of the different Ras 
isoforms to activate Raf proteins. K-Ras is more efficient in recruiting C-Raf to the plasma 
membrane than N-Ras and H-Ras, and N-Ras is more effective than H-Ras (Yan et al. 1998; 
Voice et al.1999). B-Raf is stimulated by K-Ras in a phosphatidylserine-dependent fashion, 
whereas H-Ras is able to increase B-Raf activity independent of this phospholipid (Kuroda et 
al. 1996). 
The differences in Raf-isoform-specific binding of Ras-family members may be due to 
different binding affinities to the RBD of the Raf isozymes (Weber et al. 1999). The binding 
affinities of isolated A-Raf-RBD for H-Ras, TC21, and Rap1A were markedly diminished 
compared to those of C-Raf and B-Raf-RBDs. The interacting amino acids in Ras/Raf 
interface are identical for C-Raf and B-Raf, but there is a change from arginine to lysine in the 
A-Raf-RBD at the residue corresponding to position 59 in C-Raf. These data suggest that C-
Raf and B-Raf act as preferential effectors for Ras, and that there may be different activators 
for A-Raf. 
Ras-binding does not activate Raf directly, but seems to serve for translocation of Raf 
from the cytosol to the membrane where subsequent activation events occur (Dhillon and 
Kolch 2002). These comprise a complex series of events, starting with dephosphorylation of 
S259, which allows phosphorylation of S338 and possibly Y341 as well as two sites in the 
activation loop. These modifications work together not only to determine the quantity of 
signaling output, but also regulate its quality (Dhillon et al.2003)   
The Rho family of small GTPases has been implicated in C-Raf activation. The Rho 
family which consists of Rho, Rac and Cdc42, regulates cytoskeletal structures such as stress 
fibers, lamellipodia and filopodia, respectively. However, these small G-proteins do not bind 
Raf directly but signal via activation of downstream kinases such as PKN1, PRK2 and 
ROCK1, where Rac and Cdc42 can signal through p21 activated kinase (PAK). For C-Raf 
activation the phosphorylation of S338 by PAK is crucial (King et al. 1998; Chaudhary et al. 
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2000). Consistent with the role of PAK, the upstream activators Rac and Cdc42 cooperate 
with Ras to activate C-Raf (Li et al.2001). The Rho family of small GTPases is a critical 
mediator which contributes indirectly to Ras-induced activation of Raf.  
TC21 is another member of the family of the small G-proteins which binds B-Raf and 
at least the cysteine rich region of C-Raf involved in C-Raf activation (Rosario et al. 1999). 
 
 
I.4.1.2. PKA and cAMP 
 The cAMP dependent Protein kinase A (PKA) differently regulates the three Raf 
isoforms. It is able to phosphorylate serine 43 of C-Raf, which inhibits the C-Raf kinase 
activation (Schramm et al 1994, Wu et al 1993). Additionally, Rap1 interacts with the RBD 
and CRD of Raf in competition with Ras binding (Hu et al. 1997) and antagonizes the Raf 
activation by Ras (Kitayama et al. 1989; Sacoda et al. 1992). In PC12 cells C-Raf activity is 
blocked by PKA, while B-Raf is activated and the differentiation of PC12 cells is promoted 
(Vossler et al. 1997; Ohtsuka et al. 1996; York et al. 1998). In neurons cAMP activates Erk in 
a Rap1/B-Raf dependent manner, while in astrocytes cAMP decreases Erk activity by 
inhibition of C-Raf. Thus B-Raf appears to be the molecular switch, which causes differential 
regulation of Erk in neurons versus astrocytes in response to cAMP (Dugan et al. 1999) 
 
 
I.4.1.3. 14-3-3 proteins 
 14-3-3 proteins are expressed in most tissues and are highly conserved during the 
evolution. They form homo- and heterodimers in which each monomer is able to bind proteins 
implicated in signal transduction resulting in tetrameric complexes. Different 14-3-3 isoforms 
(e.g. β, ζ, ε, η, θ) interact with various Raf family members and are necessary for the stability 
of the inactive as well as the fully active conformation of Raf (Tzivion et al. 2002; Papin et al. 
1996).  
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Figure 1-2 Raf regulatory mechanisms   (adapted from Hagemann and Rapp 1999) 
 
In the cytoplasmic conformation the N-terminal regulatory half of the Raf protein 
probably interacts with its own kinase domain (Daum et al. 1994, Morrison et al. 1997). This 
structure is presumably stabilized by binding of the 14-3-3 dimer to the phosphoserines 259 
and 621 (C-Raf) (Tzivion et al. 2002) (Fig.1-2). Binding of active Ras to the RBD and the 
cysteine-rich region of Raf displaces the 14-3-3 proteins at least from serine 259 (Rommel et 
al. 1996), possibly from both binding sites (Roy et al. 1998). This leads to opening of the 
protein structure and causes a basal activation. Then the active Raf is able to dissociate from 
Ras and to transmit the signal to its substrate MEK in the cytoplasm. 
 14-3-3 proteins are able to serve as adapter proteins. 14-3-3 proteins are highly helical 
proteins. They interact via their N-termini with each other and form a large negatively charged 
channel which is responsible for recognition of target proteins (Petosa et al. 1998). For 
example the serine/threonine kinase Bcr forms a complex with 14-3-3 and associates with 
membrane bound C-Raf.  
I.5. The role of Raf proteins in vivo 
Mice with a targeted genetic disruption of the A-Raf gene revealed neurological and 
intestinal abnormalities, abnormal movement, tremor and rigidity in musculature. The mice 
died from extensive bowel distension between day 7 and 21 postpartum (Pritchard et al. 
1996). However, the lack of A-Raf did not affect the regulation of ERK in mouse embryonic 
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fibroblasts or the transformation of these cells, suggesting that these functions are 
compensated for by other Raf family members (Mercer et al. 2002).     
 B-Raf knockout mice die in utero around day 12.5 (Wojnowski et al. 1997). They have 
increased number of embryonic endothelial progenitor cells, increased apoptosis of 
differentiated endothelial cells, and dramatically enlarged and ruptured vessels leading to 
massive hemorrhage into major body cavities. They show subtle anatomical abnormalities in 
neuronal tissue with disturbed growth and differentiation of the neuroepithelium.  
 The phenotype of the C-Raf knockouts is dependent on the genetic background. Target 
disruption of the C-Raf gene in an inbred background results in a lethal phenotype between 
E10.5 and 12.5, although the mice still express low amounts of a N-terminal truncated form of 
C-Raf with reduced kinase activity. In the outbred background 129/OLA the mice develop to 
term, are born, and die within hours after birth, because their lungs fail to inflate. They show 
general growth retardation and defects in placenta, skin, and lungs (Wojnowski et al. 1998) 
 These findings indicate that the Raf proteins play essential roles during embryonal 
development and organogenesis. While A-Raf is apparently important for the intestinal and 
neurological development, B-Raf regulates vascularization and suppresses programmed cell 
death, and C-Raf is involved in growth control and skin, lungs, and placental development. 
The dependence of A- and C-Raf phenotypes on the genetic background implies that other 
genetic modifiers or the other Raf isoforms can partially compensate for the lack of one Raf 
isozyme. The phenotype of C-Raf and B-Raf mutants is exacerbated in the absence of 
functional alleles of the other gene (Wojnowski et al. 1998). When a C-Raf mutant is crossed 
into a B-Raf mutant background, the loss of one additional Raf allele (C-Raf-/- /B-Raf-/+ or C-
Raf-/+ /B-Raf/-) increases dramatically the abnormalities. On the molecular level it results in 
complete loss of ERK activation and severely reduced expression of downstream 
transcriptional targets c-Fos, Egr-1 (O`Neil and Kolch 2004). The phenotype is characterized 
with underdevelopment of brain and head structures, defects in heart and limbs. All this leads 
to the death of 90% of the embryonic lineages, but had no effect on cell proliferation and 
implantation of the embryo. Embryos developed to small clumps of cells, divided into two 
distinct lineages closely resembling the inner cell mass and the trophoblast cells of the mouse 
blastocyst (Wojnowski et al. 1999; Mikula et al. 2001; Huser et al. 2001). 
 The results suggest that in addition to their unique functions, B-Raf and C-Raf may 
cooperate during embryonic development. The molecular mechanism of the cooperation 
between B-Raf and C-Raf is not well understood. It could be related to the ability of C-Raf to 
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heterodimerise with B-Raf. The heterodimer, conceivably, could have different signaling 
properties than either of the individual proteins alone (O`Neil and Kolch 2004).  
 I.6. Anticoagulant properties of the endothelium 
 A crucial physiologic function of the endothelium is to facilitate blood flow by 
providing an antithrombotic surface that inhibits platelets adhesion and clotting. When the 
endothelium is perturbed by physical forces or by specific chemical factors, the cells undergo 
programmatic biochemical changes that culminate in their transformation to a prothrombotic 
surface. A dynamic equilibrium exists between these two states, modulated both at the level of 
gene transcription and at the level of the intact cell that often permits the injured endothelium 
to return to its unperturbed state once the procoagulant stimuli has dissipated (Fig. 1-3). 
  
Figure 1-3 Model of activation of intravascular coagulation, where the main participants are the injured 
endothelium and the factors from the coagulation cascade released by the activated blood cells.  
         (From Engelmann et al. 2003) 
 
 Control of thrombin generation is a pivotal step in the balance between the natural 
antithrombotic and the induced procoagulant activities of the endothelium. Thrombin, a serine 
protease, serves diverse functions in coagulation, including the activation of platelets and of 
several coagulation enzymes. Several highly regulated pathways have evolved to constrain the 
generation and activity of thrombin (Rosenberg and Rosenberg 1984). The matrix surrounding 
the endothelium contains heparan sulfate and related glycosaminoglycans (GAGs) that 
promote the activity of the cell/matrix associated antithrombin III (AT-III) (Marcum and 
Rosenberg 1984). The endothelium also supports the anticoagulant influence of thrombin by 
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expression of thrombomodulin (TM). Binding of thrombin to TM facilitates the enzyme’s 
ability to activate the anticoagulant protein C. In turn the activity of activated protein C (APC) 
is enhanced by its cofactor protein S, which is synthesized by ECs, among other cell types 
(Fair et al. 1986). ECs express also receptors for APC (Fukodome et al.1996) that regulate the 
activity of this pathway.  
 All these mechanisms were already known as anticoagulant mechanisms prior to 1983. 
Today, tissue factor (TF) is considered as the main and basic inducer of the coagulation 
cascade. Although there were earlier indications that an inhibitor of TF/VIIa complex may be 
present in the serum, compelling evidence for such an inhibitory mechanism was not 
discovered until 1983 in Rapaport’s laboratory.  
 The Rapaport’s laboratory found that the VIIa/TF inhibitor is a trivalent Kunitz-type 
inhibitor, previously referred to as the extrinsic pathway inhibitor (EPI) or the lipoprotein 
associated coagulation inhibitor (LACI), and now termed tissue factor pathway inhibitor 
(TFPI) (Sanders et al. 1985; Broze et al. 1990). The endothelium is generally recognized as 
the main source of TFPI.  
I.6.1. TFPI gene structure and regulation 
 
 The TFPI gene has been mapped to chromosome 2 at region 2q31-2q31.1 (Girard et 
al.1991; van der Logt et al. 1991). It spans approximately 70 kb and consists of nine exons 
and eight introns (Fig. 1-4). 
 
 
Figure 1-4 Expression of the TFPI protein from the TFPI gene. TFPI mRNA is transcribed from the 
TFPI gene, which consists of 9 exons. After the signal peptide is released from the TFPI preprotein, full-length 
TFPI is expressed. By the action of various proteases, a truncated form of TFPI is produced. N indicates N-
terminal portion; K1, K2, and K3, Kunitz domains 1, 2, and 3, respectively; and C, C-terminal portion 
        
          (From Kato H. 2002) 
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The entire exons 1 and 2 make up the 5’ untranslated region of the TFPI mRNA, exon 
3 codes for the signal peptide and the NH2-terminal of the TFPI protein. Exons 4, 6 and 8 
code for the three Kunitz-type domains, and exons 5 and 7 code for the linker regions. Exon 9 
codes for the C-terminal of TFPI, as well as the entire 3’ untranslated region. The TFPI 
mRNA found in the endothelium and various other cell types exist as a 4 kb and 1.4 kb 
species (Bajaj et al. 1990; Girard et al.1989). The difference between the two mRNA sizes is 
attributed to the presence of ~2.6 kb additional untranslated sequences in the 4 kb transcript. 
TFPI has two isoforms known as alpha and beta that result from alternative splicing. The beta 
isoform is the shorter one with 251 amino acids translation product, and the alpha isoform has 
304 amino acids, where 28 are signal peptide (Zhang J et al. 2003). 
 A unique transcription initiation site for TFPI mRNA synthesis has not been mapped; 
neither a consensus TATA box nor a CCAAT sequence. Instead two major transcription 
initiation sites have been identified in the 5’ flanking region at cytosines 508 and 521 (Girard 
et al.1991; van der Logt et al. 1991). Two NF-1 (TGF-β- like response elements) and two AP-
1 sites (phorbol ester response elements) with imperfect sequence homology have been 
reported (Tyson et al. 1993) Additionally, four perfect and one imperfect GATA motifs have 
been identified, which act as cis-regulatory elements, three of them closely flanking the major 
transcription initiation sites. GATA motifs in TFPI gene may bind the GATA-2 transcription 
factor, which is also expressed in endothelium, and thereby regulate TFPI gene expression 
(Bajaj et al 1994; Ameri et al. 1992). Also one SP-1 site, known for its role in the 
transcription activation of TATA-less promoters, and two c-Myc sequences are believed to 
play a role in the tissue specific expression of TFPI. Notably, no sites for OCT-1, OCT-2, 
NFκB, AP-2, CREB or CRE have been identified in the sequenced regions (Petit et al. 1999). 
  Recently, a second related gene named TFPI-2 has been identified on chromosome 7 
into the human genome. Its product is also a Kunitz type inhibitor, but less potent than TFPI 
and more engaged as a blocker of other serine proteases (Chand et al. 2004). 
I.6.2. TFPI synthesis and distribution  
 
 TFPI is synthesized primarily by the vascular endothelium under normal physiologic 
conditions (Bajaj et al. 1990), and restricted to the microvascular endothelium and 
megakaryocytes (Werling et al. 1993). The expression of the TFPI gene by the endothelium of 
different organs appears to vary, probably based on the physiologic demands of the tissue. 
Lungs and heart express the highest quantities of TFPI mRNA in human and mice (Bajaj et al. 
1999). Importantly, cells that do not synthesize TFPI under physiologic conditions in adults 
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are hepatocytes, neutrophils and lymphocytes (Osterud et al. 1995). In human fetus TFPI is 
expressed in the endothelium, liver, as well as in the epithelium of the lung, kidney, intestine, 
and it is abundantly present in placental syncytiotrophoblasts and cytotrophoblasts (Edstrom 
et al. 2000), where it helps to maintain the blood in a fluid state. 
 TFPI expression can be modulated in response to various stimuli. Shear stress applied 
to human endothelial cells increases TFPI expression at around two-fold (Grabowski et al. 
2001). Thrombin may release cellular TFPI from the vascular endothelium and contribute to 
an increase in plasma TFPI with a simultaneous increase in endothelial surface TFPI (Lupu et 
al. 1995). Higher TFPI levels are observed when heparin is administrated intravenously in 
part because of the release the endothelial glucosaminoglycan-bound TFPI. These 
observations may explain some of the anticoagulant effects of heparin (Sandset et al. 1988). 
 TFPI is distributed in three pools in vivo; ~80-85% is associated with the endothelial 
surface, ~10% circulates in plasma in association with lipoproteins and a small amount in free 
form, and ~ 5% to 10% is found in platelets (Broze et al. 1994). TFPI associated with plasma 
lipoproteins is C-terminally truncated, and is a less efficient anticoagulant compared with the 
full length TFPI (Wesselschmidt et al.1992). 
I.6.3. TFPI protein structure and function 
 
 The translated amino acid sequence from the human TFPI cDNA consists of 276 
amino acids with 18 cysteines and three potential N-linked glycosylation sites. The molecular 
weight of the protein varies depending on the complexes it takes part and the level of 
glycosylation. The translated protein is around 34 kDa, the plasma lipoprotein associated form 
(LDL, HDL, VLDL) is between 35-45 kDa, and the platelets glycosylated form is at around 
45-47 kDa. TFPI contains a highly negatively charged amino terminus, three repeated Kunitz-
type domains in tandem with intervening linker regions, and a highly positively charged 
carboxyl terminus (Wun et al. 1988).  
The domain 1 (K1) of TFPI binds to factor VIIa and domain 2 (K2) binds to factor Xa. 
The precise function of the third Kunitz-type domain is not fully understood, but it has no 
inhibitory properties (Girard et al. 1989). The mechanism of inhibition of TFPI involves first 
inactivation of factor Xa, followed by binding to the VIIa/TF complex (Baugh et al. 1998) 
(Fig.1-5). Importantly, the Xa-TFPI complex is a much more potent inhibitor of VIIa-TF than 
TFPI by itself. 
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Figure 1-5 Inhibitory mechanisms of the initial reaction of blood coagulation by TFPI on cell surfaces. 
TFPI binds to factors VIIa and Xa via the K1 and K2 domains and to proteoglycans via K3 and C-terminal 
domains.         (Adapted from Kato H. 2002) 
 
 
 Although a number of additional targets for attachment are reported, the C-terminal 
basic region appears to play an important role in binding TFPI to cell surfaces. TFPI has an 
important function in embryonic development because TFPI homozygote gene knockout mice 
die around day 9.5-11.5 characterized by retardation of embryonic growth and hemorrhages in 
the central nervous system, tail and the yolk sac. The heterozygote TFPI knock outs are viable 
and reproductive; they have around 50% reduced amounts of TFPI in the plasma and 
increased risk of atherosclerosis and thrombosis (Huang et al. 1997; Westrick et al. 2001) 
 
I.6.3.1. Proteolytic digestion of TFPI 
 In many inflammatory conditions the activated leukocytes release several types of 
proteases, and TFPI is one of their substrates. TFPI is indeed cleaved by serine proteases, 
including elastase (Petersen et al. 1992; Higuchi et al. 1992), cathepsin G (Petersen et al. 
1992), as well as by different matrix-metalloproteinases (Belaaouaj et al. 2000; Cunningham 
et al. 2002). Proteases included in the blood coagulation also take part in the TFPI 
degradation, such as thrombin (Ohkura et al. 1997), factor Xa (Salemink et al.1998), and 
plasmin (Stalboerger et al. 2001). The sites of cleavage in the TFPI molecule are denoted on 
Fig.1-6. Proteolytic degradation of TFPI increases the activity of its antagonist tissue factor, 




Figure 1-6 Sites within TFPI susceptible to proteolytic degradation. Sites of cleavage by MMP-8 and 
other proteinases, including MMP-1, -7, -9, -12, human neutrophil elastase (HNE), thrombin, plasmin and 
cathepsin G (Cat G) are denoted by arrows on the diagram of the primary amino acid sequence and Kunitz 
domain structure.        (From Cunningham et al. 2002)
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I.7. Aims of the investigation 
 
During the last years, increasing evidence has indicated an important role for the 
endothelial cells and their precursors in vasculogenesis, angiogenesis, and anticoagulant 
processes. The Raf family proteins are part of the main signal transduction pathways 
regulating the homeostasis of the endothelial cells. It was therefore of interest to explore the 
functions of the Raf proteins in differentiation and proliferation of the eEPCs. To this purpose, 
we prepared gene constructs allowing us to activate or inhibit the downstream signaling of B-
Raf and C-Raf. To further delineate the participation of the endothelium in coagulation, the 
role of native TFPI and its mutated forms in intravascular fibrin formation was analyzed. 
Particular attention was given to mutants being resistant towards cleavage by leukocyte 
proteases that might inactivate TFPI under physiological and pathophysiological conditions. 
In the present study, we addressed the following questions: 
 
1. What is the role of B-Raf and C-Raf in the differentiation and proliferation 
of the embryonic endothelial progenitor cells? 
2. How do these cells respond to a regulatable over expression of the kinase 
domains of B-Raf and C-Raf? 
3. How are the functions of the eEPCs affected by the “knock down” of both 
B-Raf and C-Raf? 
4. What is the role of the native TFPI and its different mutated forms for the 
coagulation start within the blood vessel?  
5. Do alterations of proteolytic cleavage sites modify the anticoagulant 
behaviour of TFPI? 
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Items       Companies, Type 
Bacterial incubator      Heraeus B 6200 
Bacterial shaker      New Brunswick Scientific innova 4330 
Cell culture incubator     Köttermann 
Cell culture microscope     Carl Zeiss 
Chromatography columns (0.8 x 4 cm)   Bio Rad 
Coulter counter     Becton Dickinson 
Culture Hood       HLB2472, BIO-FLOW Technik 
Developing machine      AGFA 
Electrophoresis power supply EPS600,   Pharmacia 
Electrophoresis unit, small    Bio-Rad Mini-Protean II 
ELISA Reader Dynatech MR7000   Dynatech Laboratories 
Fine scale       Scaltec SBC 21 
Gel dryer       Bio-Rad Gel Dryer 583 
Heat block       Liebisch, Type 2099-DA 
Horizontal electrophoresis gel    MWG Biotech 
Mega centrifuge      J-6B,Beckman; Megafuge 1.0 R, Heraeus; 
RC 5B plus, Sorval 
Mini centrifuge      5417R, Eppendorf 
pH meter       Microprocessor, WTW 
Shakers       Heidolph, Unimax 2010, Edmund Bühler 
Scale        BP2100S, BP310S, Sartorius 
Spectrophotometer      U-2000, Hitachi 
Thermocycler      Byozim  
Thrombelastograph RoTEG    Dynabyte  
Vortex       Scientific Industries Genie-2 
Water bath       GFL 1083, Amersham-Buchler 
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II.1.2. Reagents and general materials 
 
Items        Companies 
1 kb DNA ladder      Sigma 
100 bp DNA ladder     New England Biolabs 
Acetyl-CoenzymA      Sigma 
Acrylamide (30%)/Bisacrylamide (0,8%)   Roth 
Adenosin-5’Triphosphate (ATP)    Sigma 
Agarose, ultra pure      Life Technologies, Inc. 
Ammonium peroxydisulfate (APS)    Sigma 
Ampicillin       Sigma 
Anhydrotetracyline     IBA 
Aprotinin       Roth 
Bacto-Agar       Roth 
Beriplex PN 500     Behring 
Bovine serum albumin (BSA)    Sigma 
Bradford-reagent      Biorad 
Bromphenolblue      Sigma 
Calciumchloride (CaCl2)     Sigma 
Dimethylsulfoxide (DMSO)     Sigma 
Dithiothreitol (DTT)      Sigma 
dNTP        Roche 
Ethylenediaminetetraacetic acid (EDTA)  Sigma 
EGTA       Sigma 
Ethanol       Roth 
Ethidiumbromide      Life Technologies, Inc. 
Glutathion-sepharose     Pharmacia 
Glycerol       Sigma 
Glycine       Roth 
Hydrochloride (HCl)      Roth 
4-hydroxyazobenzene-2-carboxylic acid-HABA IBA 
HEPES      Roth 
Isopropanol       Merck 
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Kanamycin      Sigma 
Leupeptin       Sigma 
Magnesiumchloride      Sigma 
Nitrocellulose membrane     Schleicher & Schüll 
Pefablock       Roth 
PMSF       Roth 
Ponceau S       Sigma 
Potassium acetate (KAc)     Sigma 
Potassiumchloride (KCl)     Sigma 
Potassiumdihydrophosphate (KH2PO4)   Merck 
Protein A-agarose      Roche 
Protein marker (SDS-7B)     Sigma 
SDS ultra pure      Roth 
Sodiumdihydrophosphate (NaH2PO4)   Merck 
Sodiumhydrophosphate (NaHPO4)    Merck 
Sodiumhydroxide (NaOH)    Sigma 
Sodium orthovanadate     Sigma 
Strep-Tactin II      IBA 
S2222       Haemochrom diagnostica 
TEMED       Roth 
Tris-(hydroxymethyl)-aminomethane (Tris)  Roth 
Triton-X100       Sigma 
Whatman 3MM Papier     Schleicher & Schüll 
X-ray film       Amersham-Buchler 
Xylencyanol       Roth 
Yeast extract       Life Technologies, Inc. 
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II.1.3. Cell culture materials 
 
Items        Companies 
Lypofectamin 2000 TM     Life Technologies, Inc. 
Oligofectamine      Life Technologies, Inc. 
Fetal bovine serum (FBS)     GIBCO 
L-Glutamine       Life Technologies, Inc. 
G-418 (antibiotic)     Invitrogen 
Penicillin /Streptomycin     Life Technologies, Inc. 
DMEM       Life Technologies, Inc. 






Items        Companies 
Calf Intestinal Phosphatase (CIP)    New England Biolabs 
DNase       Qiagen 
Pfu Taq Polymerase      Stratagene 
Pfx Platinum Polymerase     Invitrogen 
Reverse transcriptase     Invitrogen 
RNase       Roche 
T4 DNA Ligase      New England Biolabs 
Vent Polymerase     New England Biolabs 
 
General restriction enzymes are purchased from Fermentas and New England Biolabs 
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II.1.5. Antibody conjugates 
 
Antibodies    Antigens    References 
anti-ER (C-14)  ER     Santa Cruz (sc-154) 
anti-B-Raf (C-19)  B-Raf    Santa Cruz (sc-166) 
anti-C-Raf (C-12)  C-Raf    Santa Cruz (sc-133) 
anti-B-Raf   B-Raf    Upstate (07-453) 
anti-C-Raf    C-Raf    Upstate (07-396) 
anti-MEK1/2   MEK1/2   Cell signaling technology (9122) 
anti-Phospho-MEK1/2 Phospho-MEK1/2  Cell signaling technology (9121) 
anti-TFPI (C-20)  TFPI    Santa Cruz (sc-18713) 
anti-Mouse IgG conjugated peroxidase (POD)  Dianova 
anti-Rabbit IgG conjugated peroxidase (POD)  Dianova 





Items        Companies 
ECL Western blotting detection reagents   Amersham 
Gene TailorTm Site-Directed Mutagenesis Kit Invitrogen 
Macs magnetic microbeads cell isolation Kit  Milltenyi Biotech 
QIAGEN Gel Extraction Kit    Qiagen 
QIAGEN Plasmid Kit (Midi, Maxi)    Qiagen 
QIAquick PCR purification Kit    Qiagen 





pPGK ß-gal pA   Hatzopoulos A.K. 
pPGK ß-geo pA   Hatzopoulos A.K. 
pPGK neo pA    Hatzopoulos A.K. 
pPGK EGFP pA   Hatzopoulos A.K. 
pPGK ER-B-Raf pA   in this work 
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pPGK ER-C-Raf pA   in this work 
pBK-CMV    Clontech 
pBK-CMV-B-Raf   in this work 
pBK-CMV-C-Raf   in this work 
pASK-IBA3    IBA 





All the primers were synthesised by MWG-Biotech AG 
II.1.8.1. Cloning primers 
Primer  Restriction site Sequence 
ER forward  (BamHI)  5’-ATTCCACCATGGATCCATCTGCTG-3’  
ER reverse  (EcoRI)  5’-GAATGTAGGCATGAATTCGACTGTGG-3’ 
B-Raf forward  (EcoRI)  5’-GGAATTCGTGAAAGCCTTACAGAAATCTCCAG-3’ 
B-Raf reverse  (XhoI)   5’-CCGCTCGAGGGTGTTTCAGTGGACTGG-3’ 
C-Raf forward  (EcoRI)  5’-GGAATTCAGTCCAACAGGCTGGTCACAG-3’ 
C-Raf reverse   (SalI)   5’-ACGCGTCGACCTAGAAGACTGGTAGCCTTG-3’ 
TFPI forward  (BamHI)  5’-CGGGATCCGCTGATTCTGAGGAAG-3’ 
TFPI reverse  (EcoRI)  5’-GGAATTCGCTGATTC TGAGGAAG-3’ 
II.1.8.2. Site directed mutagenesis primers 
Primer    Sequence 
TFPI L21A forward   5’-GAGTTGCCACCACTGAAAGCTATGCATTCATTTTG-3’ 
TFPI L21A reverse    5’-CAGTGGTGGCAACTCCGTATCTGTGATAATTG-3’ 
TFPI T87F forward   5’-CAAACAGGATTATAAAGTTTACATTGCAACAAG-3’ 
TFPI T87F reverse   5’-CTTTATAATCCTGTTAGCAATATCTCTTG-3’ 
TFPI L89A forward   5’-GGATTATAAAGTTTACAGCGCAACAAGAAAAGC-3’ 
TFPI L89A reverse   5’-TGTAAACTTTATAATCCTGTTTGCATTATCTC -3’ 
TFPI Y159A forward   5’-GGTTTCCAGGTGGATAATGCTGGAACCCAG-3’ 
TFPI Y159A reverse   5’-ATTATCCACCTGGAAACCATTCGGACCATC-3’ 
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II.1.9. Bacteria strains and cell lines 
 
Cell line   Species   Classification    Reference 
DH5α   E.coli   bacterial cells    Invitrogene 
BL21 
 
eEPCs   M. Musculus  embryonic endothelial cells  Hatzopoulos
      progenitor cells   et al. 1998 
  
 
II.1.10. Bacterial and cell culture media 
 
D 7.5 media (embryonic endothelial progenitor cells) 
77% DMEM 25 mM Hepes 
(Without Sodium Pyruvate, with 4500 mg/l Glucose, with Pypidoxine) 
20% Fetal Bovine Serum 
1% L-Glutamine 
1% Pen/Strep 
1% non essential amino acids 
ß-Mercaptoethanol 3,5 µl per 500 ml 
 
Freeze Medium for eEPCs 
90% Fetal Bovine Serum 
10% DMSO 
 
LB (Luria-Bertani) medium 
1% Bacto-tryptone 
1% NaCl,  
0.5% Bacto-yeast extract 
Adjust pH to 7.5 with NaOH and total volume to 1 L with H2O 
For plates, add 15 g Bacto-agar 
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2x TY medium 
16 g Bacto-tryptone 
10 g Bacto-yeast extract 
5 g NaCl 
Adjust pH to 7.4 with NaOH and total volume to 1 liter with H2O 







0.15% bovine serum albumin 
In phosphate-buffered saline (PBS)  
 
Blotting Buffer (for transferring the proteins to the nitrocellulose membrane) 
150 mM Glycine 





5% (w/v) of nonfat dry milk in TBST 
 
Buffer HSB (electroporation) 
25 mM Hepes pH 7.1 
134 mM NaCl 
5 mM KCl 
0.7 mM Na2HPO4 
 
Buffer for IP (lysis and wash) 
20 mM Tris, pH 7.5 
5 mM MgCl2 
10 mM EGTA 
1% Trion X-100 
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50 mM NaF 
0.7 mM Na4P2O7 
0.7 mM Na2VO4 
1 mM PMSF* 
10 µg/ml aprotinin before use* 
10 µg/ml leupeptin before use* 
*- directly before use just for the lysis. 
 
Buffer NX 10x (reverse transcription) 
0.4 M KCl 
0.1 M Tris-HCl, pH 8.4 
20 mM MgCl2 
2% Tween 20 
 
Buffer P1 (Resuspension buffer) 
50 mM Tris-HCl, pH 8.0 
10 mM EDTA 
10 mg/ml Rnase A 
 
Buffer P2 (Lysis buffer) 
10% SDS 
200 mM NaOH 
 
Buffer P3 (Neutralization buffer) 
3 M potassium acetate, pH5.5 
 
Buffer QBT (Equilibration buffer) 
15% ethanol 
0.15% Triton X-100 
 
Buffer QC (Wash buffer) 
2.0 M NaCl 
50 mM MOPS, pH7.0 
15% ethanol 
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Buffer QF (Elution buffer) 
1.25 mM NaCl 
50 mM Tris-HCl, pH 8.5 
15% ethanol 
 
Set Qiagen RNA isolation buffers 
Buffer RLT- cat Nr. 79216 
Buffer RW1- cat Nr. 79216 
Buffer RPE -cat Nr. 79216 
 
1x CIP Buffer 
50 mM NaCl 
10 mM Tris-HCl 
10 mM MgCl2 
1 mM dithiothreitol , pH7.9 
 
10x DNA Gel Loading Buffer 
40% (w/v) saccharose 
0.25% bromphenolblue 
0.25% xylencyanol, use as 1x solution 
 
Lysis Buffer (for cell culture) 
50 mM Na-MES, pH 7.8 
50 mM Tris-HCl, pH 7.8 
10 mM DTT 
2% Trion X-100 
Phospate-Buffered Saline (PBS) 
136 mM NaCl 
2.6 mM KCl 
10 mM Na2HPO4, 
1.5 mM KH2PO4, pH7.4 
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Running Buffer (for SDS-PAGE) 
25 mM Tris 
250 mM Glycine 
0.1 % SDS 
 
5x SDS-loading buffer (for SDS-PAGE) 
31 mM Tris HCl, pH6.8 
1% SDS 
5 % Glycerin 
2.5 % Mercaptoethanol 
0.05 % Bromphenoblue, work at 1x solution 
 
Sodium Tris-EDTA buffer (STE) 
100 mM NaCl 
10 mM Tris-HCl, pH 8.0 
1 mM EDTA 
 
TLB buffer 
20 mM Tris, pH 7.4 
50 mM Sodium glycerophosphate 
20 mM Sodium pyrophosphated 
500 mM NaCl 
10 % (v/v) glycerol 
0.1% Triton X-100 
2 mM EDTA 
1 mM pefablock 
1 mM sodium orthovanadate 
5 mM benzamidine 
5 µg/ml aprotinin before use 
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1x Tris-Acetate-EDTA (TAE) 
40 mM Tris-HCl, 
40 mM acidic acid, 
2 mM EDTA; pH7.8 
 
10x Tris-Borate-EDTA (TBE) 
108 g Tris base 
55 g boric acid 
20 ml 0.5 M EDTA, pH 8.0 
Adjust the volume to 1 liter with H2O 
 
1x Tris-Buffered Saline (TBS) 
10 mM Tris-HCl, 
137 mM NaCl 
 
TBST 
1x TBS + 0.1% Tween 
 
Washing buffer (protein isolation) 
100 mM Tris/HCl, pH 8.0,  
150 mM NaCl, 
1.0 mM EDTA,  
0.02% w/v NaN3  
 
Elution buffer (protein isolation) 
100 mM Tris/HCl, pH 8.0, 
150 mM NaCl, 
1.0 mM EDTA,  
0.02% w/v NaN3,  
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Regeneration buffer (protein isolation) 
100 mM Tris/HCl, pH 8.0, 
150 mM NaCl, 
2 mM EDTA,  
0.02% (w/v) NaN3,  
5 mM of 4-hydroxyazobenzene-2-carboxylic acid (HABA) 
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II.2. Methods 
 
II.2.1. Cell cultures 
 
 
II.2.1.1. Bacterial cultures 
Plasmid transformed bacteria were selected on LB plates with ampicillin (100 µg/ml) 
or kanamycin (50 µg/ml) for 24 hr. For overnight mini cultures, 1 colony was picked and 
inoculated in LB medium with appropriate antibiotics and shaken overnight at 37°C. The 
culture was then used for preparing frozen glycerine cultures, plasmid DNA or fusion protein 
purification. For storage of bacteria, a glycerol stock culture was prepared by growing bacteria 
in culture medium and the OD was measured with a photometer at a wavelength of 600 nm. 
When the OD reached 0.8, the bacterial culture was added to 500 µl 80% glycerine and then 
mixed thoroughly in a small 1.5 ml tube. This stock solution was subsequently frozen at –
80°C. To start an overnight culture again, bacteria were held at room temperature (RT) until 
the surface was thawed. A small amount of cells was picked and mixed into 2-5 ml culture 
medium and left to grow for several hours at 37°C in a bacterial culture shaker. The frozen 
stock was immediately returned to storage at –80°C. 
 
II.2.1.2. Preparation of competent cells (CaCl2 method) 
An overnight preculture was started from a single colony on a petri dish in 2 ml LB 
media by incubation at 37°C and was shaken for oxygenation. The second day, 1 ml of the 
preculture was inoculated in 100 ml fresh media and the culture was grown at 37°C until the 
OD at the wavelength of 600 nm reached 0.2 to 0.4. The culture was cooled down on ice for at 
least 15 min. The following steps were done at 4°C in pre-cooled sterile tubes. The cells were 
harvested by a 5-min centrifugation at 5000 g, and the supernatant was discarded. The 
bacterial pellets were thoroughly resuspended in a small volume of ice-cold 100 mM CaCl2. 
The suspension was diluted with the CaCl2 solution to a final volume of 30-40 ml, and left on 
ice for 25 min with occasionally shaking. The cells were span down as before, the supernatant 
was carefully discarded and the pellets were resuspended in 5 ml glycerol/CaCl2. The 
suspension was aliquoted in 100 to 400 µl and stored at –70°C. The transformation efficiency 
of the bacteria prepared by this method should reach at least 106 cells. 
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II.2.1.3. Transformation of competent bacteria 
The competent bacteria were thawed on ice. At around 40ng ligated-DNA or purified 
plasmid-DNA was added to 100 µl competent cells in a cold 1.5 ml microfuge tube, then 
mixed carefully and kept on ice for 20 min or longer. The bacteria were heat-shocked at 42°C 
for 90 sec, 1 ml antibiotic-free LB medium was added, and oxygenated at 37°C for 30 min. 
Selection of transformed bacteria was done by plating 100 µl of the bacterial suspension on 
the antibiotic-containing agar plates. Only bacteria that have taken up the desired plasmids, 
which normally contain antibiotic resistance cassette, could grow on the agar antibiotic plates. 
Some of the colonies that were grown on the plate were expanded in LB medium and used for 
DNA preparation. 
 
II.2.1.4. Maintaining of cell culture 
The mouse embryonic endothelial progenitor cell line (eEPC) was maintained in a 
special medium as described below. The cells were cultured until reaching 90% confluence 
and than split to obtain adequate density. Important for the eEPCs was the coating of the 
plates with 0.1 % gelatine for at least 10 min at 37° C for sufficient cell adhesion. 
To freeze the cells, cell cultures were centrifuged at 1100 rpm for 5 min and 
resuspended into freeze medium. Aliquotes were set into a styropore box and left to freeze 
gradually in the -80°C freezer. DMSO was added to prevent ice crystal formation and to allow 
maintenance of the integrity of the cells. After 24 hr or later, the cells were transfered to liquid 
nitrogen where they were kept for longer periods of time. 
 
II.2.1.5. Transfection of eEPCs 
 
II.2.1.5.1. Electroporation 
 For each electroporation 1.5-2X106 cells were used. The cells were trypsinized and it 
was stoped with 5 ml medium, and then resuspended in 20 ml HSB buffer. After spinning 
them down, they were again resuspended in 10 ml HSB buffer. After a new centrifugation 
step they were resuspended to a concentration of 1.5-2X106 cells in 0.8 ml HSB and 
transferred to the electroporation cuvette. 30 µg linearised plasmid was added to the cells, 
mixed well and kept 10 min on ice. Then the cells were electroporated at 350 V, 500 
microfarrads. The times were recorded concomitantly. After the electroporation the cells were 
kept 10 min on ice and transferred into 24 ml medium. The cells were plated in 2x10 cm 
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plates (gelatinised) in order to let them recover over night. The next day the selection was 
started with 200-400 µg/ml G418 (active conc.). The medium was exchanged daily. The first 
colonies were usually formed within 1-2 weeks.  
 
II.2.1.5.2. Lipofectamine transfection 
1. The day before transfection, the cells were trypsinized, counted and plated at 1-
3X105 cells per well so that they were 80-85% confluent on the day of transfection. Cells were 
plated in their normal growth medium containing serum, but in the absence of ANY 
antibiotics. 
2. For each well of cells to be transfected, 0.8 to 1.0 µg of DNA was diluted into 50 µl 
of OPTIMEM without antibiotics. 
3. For each well of cells, 1-3 µl of LF2000 Reagent was diluted into 50 µl OPTIMEM 
(as indicated above) and incubated for 5 min at room temperature. 
4. The diluted DNA (from step 2) with the diluted LF2000 Reagent (from step 3) were 
combined and incubated at room temperature for 20 min to allow DNA-LF2000 Reagent 
complexes to form. 
5. DNA-LF2000 Reagent complexes (100 µl) were added directly to each well and 
mixed gently by rocking the plate back and forth. 
6. The cells were incubated at 37°C in a CO2 incubator for a total of 24-48 h until they 
were ready to assay for transgene expression. It was not necessary to remove the complexes or 




II.2.2. DNA techniques 
 
 
II.2.2.1. Electrophoresis of DNA on agarose gel 
Double stranded DNA fragments with lengths between 0.1 kb and 10 kb can be 
separated according to their lengths on agarose gels. Agarose was added to 1x TAE to obtain a 
final concentration between 0.7-2%. The suspension was boiled in the microwave until the 
agarose was completely solubilised. The agarose was cooled down to around 50°C, before the 
ethidium bromide was added up to 0.5µg/ml and poured into the gel apparatus. DNA gel 
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loading buffer was added to the DNA sample and applied on the gel. Electrophoresis was 
performed in 1x TAE buffer at 3-8 volts/cm. The DNA fragments were visualised under UV-
light. 
 
II.2.2.2. Isolation of plasmid DNA from Agarose (QIAGEN gel extraction kit) 
This protocol is designed for the extraction of DNA fragments from 0.7-2% standard 
agarose gels in TAE or TBE buffer. DNA molecules were adsorbed to QIAGEN silica 
columns. All non-nucleic acid impurities such as agarose, proteins, salts, and ethidium 
bromide were removed during the washing steps. The desired DNA band was excised from 
the agarose gel under the UV light. The gel slice was weighed and 5 volumes of Buffer QG 
were added to 1 volume of gel for DNA fragments 100-bp 4 kb; for DNA fragments of > 4 kb, 
2 volumes of QG plus 2 volumes of H2O were added, and then incubated at 50°C for 10 min 
to solubilise the agarose. The solubilised agarose was resuspended by vortexing and the 
sample was added to the QIAGEN silica columns to bind the DNA. The sample was 
centrifuged for 30 sec. The column was washed with 500 µl of Buffer QG and then twice with 
Buffer PE. Thereafter it was centrifuged for additional 30 sec to remove residual alcohol from 
the buffers. The column was span for 1 min to elute the DNA in 30-50 µl 10 mM Tris-HCl or 
H2O. 
 
II.2.2.3. Purification of plasmid DNA (QIAquick PCR purification kit) 
This protocol is designed to purify single- or double-stranded PCR products or DNA 
plasmids ranging from 100 bp to 10 kb. DNA adsorbs to the silica-membrane in the presence 
of high salt while contaminants pass through the column. The impurities were washed away 
and the pure DNA was eluted with Tris buffer or H2O. 5 vol of buffer PB was added to 1 vol 
of the contaminants and mixed. A QIAquick spin column was placed in a 2 ml collection tube. 
The mixed sample was added to the QIAquick column and centrifuged for 30-60 sec. The 
flow-through was discarded and the QIAquick column was placed back into the same 
collection tube. 0.75 ml washing buffer (PE) was added to the column and centrifuged for 30-
60 sec. The flow-through was discarded and the QIAquick column was placed back into the 
same collection tube. The column was centrifuged for an additional 1 min at maximum speed, 
and placed in a clean 1.5 ml microfuge tube, and then 30-50 µl elution buffer (EB) or H2O 
was added to the centre of the QIAquick column and centrifuged for 1 min. The purified DNA 
was stored at – 20°C. 
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II.2.2.4. Ligation of DNA fragments 
Calf-intestinal-phosphatase (CIP) reaction (5' phosphorylation) 
Alkaline phosphatase catalyses the removal of 5' phosphate groups from DNA, RNA 
and ribo as well as deoxyribonucleoside triphosphates. For the blunt end ligation, the 5’ 
phosphate group of the vector must be removed by the CIP reaction. The same reaction is also 
used to prevent the religation of the vectors. 2.5 µg of DNA fragments were phosphorylated at 
37µC for 30 min in 100 µl of reaction volumes, consisting of 1x CIP buffer and 1µl of 
phosphatase. 5 mM EDTA was then added and the mixture incubated for 15 min at 65°C to 
inactivate the enzyme. The DNA fragments were purified by phenol and ethanol precipitation 
before the ligation reaction. 
 
II.2.2.5. Cohesive-end ligation 
The plasmid DNA or DNA fragment were prepared by cutting with suitable restriction 
enzymes, followed by their purification. 1:3 molar ratios of vector: insert DNA fragments 
were incubated together with 1 µl (1 U/µl stock) of T4 ligase in 1x ligation buffer in a total 
volume of 20 µl for 4 hr at room temperature or overnight at 16°C. The mixture was heated at 
65°C for 10 min to inactivate the enzyme. 
 
II.2.2.6. Oligonucleotide primers 
 All oligonucleotide primers were synthesized from MWG-Biotech (Germany) and 
delivered in lyophilised form. The oligonucleotides were dissolved in sterile water to obtain a 
100 pmol solution. From this primer solutions were prepared at the desired concentration, for 
conventional PCR, sequencing and site directed mutagenesis. Oligonucleotide primers used 
for the estrogen receptor (ER), B-Raf, C-Raf and TFPI cloning (bold letters show the 
restriction sites), for site directed mutagenesis of TFPI (bold letters indicate the mutated 
bases) are listed in the Materials section.  
 
II.2.2.7. Polymerase chain reaction (PCR) 
The coding regions of the kinase domains of B-Raf and C-Raf were amplified by PCR 
from mouse embryo cDNA. The hormon binding site of ER was amplified from a vector 
available in the laboratory, and the full length of TFPI was amplified by PCR from total 
carotid plaque cDNA. The reactions were performed with 3µl total cDNA, 0.2 µl/reaction 
dNTP 20 mM mix, 5µM primer mix 2 µl/reaction, 5 U/µl DNA polymerase with proof 
reading activity (Vent, Pfu) 0.5 µl/reaction, 2 µl 10X PCR buffer (in a total volume of 20 µl). 
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The PCR amplification was performed with the following protocol by varying the annealing 
temperatures and the elongation times: 
Step 1 Initial denaturation: 94°C for 2 min 
Step 2 Denaturation: 94°C for 20 sec 
Step 3 Annealing: 52-68°C for 30 sec 
Step 4 Elongation: 68°C 1 min per kilobase 
Step 5 Closing the cycle and back to step 2 
Step 6 Final elongation: 68°C for 5 min 
Step 7 End, keep at 4°C 
The conventional quantitative PCR was performed with 3µl total cDNA, 20 mM mix 
dNTP 0.2 µl/reaction, 5µM primers mix 2 µl/reaction, 5 U/µl Taq DNA polymerase 0.5 
µl/reaction, 2 µl 10X PCR buffer (in total volume of 20 µl). The PCR amplification was 
performed with the following protocol by varying the annealing temperatures and the 
elongation times: 
Step 1 Initial denaturation: 94°C for 2 min 
Step 2 Denaturation: 94°C for 20 sec 
Step 3 Annealing: 52-68°C for 30 sec 
Step 4 Elongation: 72°C 1 min per kilobase 
Step 5 Closing the cycle and back to step 2 
Step 6 Final elongation: 72°C for 5 min 
Step 7 End, keep at 4°C 
 
II.2.2.8. Mini-preparation of plasmid DNA 
3 ml overnight cultures were grown in LB media with 100 µg/ml ampicillin (or 
kanamycin, 50 µg/ml) at 37°C overnight. The cells were pelleted at 14,000 rpm for 1 min, the 
supernatant was removed, and the cells resuspended in 100 µl Buffer. 200 µl Buffer P2 (Lysis 
Buffer) was added and incubated at RT for 5 min, then 200 µl ice-cold 3 M acidic KOAc 
(Neutralisation Buffer) was added and mixed by inverting the tubes for 6-7 times. The lysates 
were incubated on ice for 5 min and centrifuged at 15,000 rpm for 3 min. The supernatant was 
transferred to a fresh eppendorf tube and 900 µl of pre-cooled 100% ethanol was added for 
precipitation at -70°C for 10 min. The pellet was centrifuged at 15,000 rpm for 10 min. 
Subsequently it was washed with 200 µl 70% ethanol and air-dried for a few min. Then it was 
resusspended in 30-50 µl of 10 mM Tris-HCl, (pH 7.8). 
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II.2.2.9. Maxi-preparation of plasmid DNA 
Bacterial cultures containing plasmids or recombinant plasmids were grown in 50 ml 
LB media overnight in a 37°C-incubator with shaking at 190 rpm. The bacteria were collected 
and DNA plasmids were isolated by using a Quiagen Plasmid Maxi Kit. This extraction 
method is based on Birnboim’s alkali lysis principle. The bacterial pellet was resuspended in 
10 ml of buffer P1. 10 ml of buffer P2 were added and mixed gently. Then the lysate was 
incubated at RT for 5 min, 10 ml of chilled Buffer P3 was added and mixed immediately, and 
further incubated on ice for 20 min. The suspension was centrifuged at 4,000 rpm for 30 min 
at 4°C and the supernatant was filtered over a prewetted folded filter. The supernatant was 
applied to an equilibrated QIAGEN-tip 500 and the resin was allowed to enter by gravity 
flow. The QIAGEN-tip was washed twice with buffer QC. The DNA was eluted with 15 ml 
buffer QF. These processes resulted in the isolation of a DNA-salt pellet, which was 
precipitated by 0.7 volumes (10.5 ml) of isopropanol, and centrifuged further at 4000 rpm for 
30 min. The resulting pellet was washed twice with 70% ethanol and air-dried at RT. The 
pellet was then carefully resuspended in TE buffer and quantified. 
 
II.2.2.10. Restriction digests 
 Digestion of DNA with restriction enzymes was performed according to the 
manufacturer’s instructions using recommended buffer systems and the appropriate reaction 
temperatures. Generally, 1 U of enzyme was needed per 1 µg DNA. The plasmid DNA was 
usually digested for 1-2 h. The completion of the reaction was monitored by agarose gel 
electrophoresis. 
 
II.2.2.11. Measurement of DNA concentration 
The DNA concentration was determined by using an UV spectrophotometer at a 
wavelength of 260 nm. Absorption of 1.0 at 260 nm corresponds to a concentration of 50 
µg/ml double stranded DNA. Identity, integrity, and possible purity of the DNA was 
subsequently analysed on an agarose gel. The ratio in absorption at 260/280 nm which is 
determining pure DNA is over 1.8. 
 
II.2.2.12. DNA Site directed mutagenesis 
 Site directed mutagenesis was performed using the Gene TailorTm Site-Directed 
Mutagenesis System- Invitrogen. The method includes in a variety of different techniques 
such as primer design, PCR, transformation of E.coli, mini and maxi preparation of plasmid 
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DNA. The method is used to exchange a single amino acid within a polypeptide chain, or to 
remove or insert up to 5 amino acids in one reaction. First it was performed methylation of the 
plasmid containing the gene of interest to mutate. The methylated parental plasmid will be 
degraded by the bacterial strain used for transformation; this will reduce the background of 
unmutagenised DNA, and will increase the efficiency. The primers were designed to contain 
the mutated bases (the TFPI primers used are listed in the Materials section). The primers 
must be overlapping and containing protruding ends to enable the recirculization of the vector. 
For the PCR of the methylated template, PlatinumR Pfx polymerase was employed, which has 
proof reading activity. After amplifying the whole construct, the transformation into the 
bacterial strain was made as supplied from Invitrogen. Detection of the transforming activity 
was done by PCR and by restriction assay (the new formed sequence could potentially form 
or destroy the restriction sites). Subsequently, sequencing was performed in order to check for 
the vector and of the mutations in the gene of interest. 
 
II.2.2.13. DNA Sequencing 
 All sequencing reactions were performed in SeqLab-Göttingen, Germany. The 
evaluation of all results was done with the PC program Chromas. 
 
 
II.2.3. RNA techniques 
 
 
II.2.3.1. Total RNA isolation from animal cells  
 The protocol is designed to isolate total RNA from animal cells with silica Rneasy 
columns (Qiagen). The cells grown in monolayer can be lysed directly on the plate. 
Depending on the cell number, 350 µl RLT lysis buffer containing ß-Mercaptoethanol (ß-ME) 
(10 µl per 1 ml RLT) were added to 5x106 cells (6 cm plate), or 600 µl was added to 5x106-
1x107 cells (10 cm plate). The lysed cells were pipetted onto a QIAshredder column and 
centrifuged for 2 min at maximum speed to be homogenized. One volume of 70% ethanol was 
added to the homogenized lysate and mixed well by pipetting. The sample was applied on the 
RNeasy spin column, and centrifuged for 15 sec at 10000 rpm, then 700 µl buffer RW1 was 
pipetted onto the column and centrifuged for 15 sec. DNAse (RNAse free) was applied on the 
column to degrade the genomic DNA; it was incubated for approx. 20 min at room 
temperature. The column was washed with new 700 µl buffer RW1. The column was 
transferred into a new 2 ml tube, 500 µl of RPE buffer were loaded onto and centrifuged for 
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15 sec at 10000 rpm. The last step had to be repeated once. Then the flow-through was 
discarded and centrifuged for 1 min at full speed to ensure that there was no alcohol left from 
the last washing step. The RNeasy column was transferred into a new tube and the total RNA 
was eluted with 30-50 µl of RNase free water, then quantified and finally stored at –80° C. 
 
II.2.3.2. Measurement of RNA concentration 
 The RNA concentration was determined by using an UV spectrophotometer at a 
wavelength of 260 nm. The absorption of 1.0 at 260 nm corresponds to a concentration of 40 
µg/ml total RNA. Identity, integrity, and purity of the RNA were subsequently analysed on an 
agarose gel. The ratio in absorption at 260/280 nm determining pure (low amount of proteins) 
RNA was over 1.8. 
 
II.2.3.3. Reverse transcriptase reaction  
 1 µg of RNA was incubated with oligo dT primers (1.25 µl of 17 µM conc.; 80 ng/µl) 
at 65°C for 5 min in order to destroy secondary structures of the RNA and to make accessible 
most of the poly A tags of the mRNA. The mix containing the reverse transcriptase 
(polymerase, 0.5 µl 200 U/µl), dNTPs 0.5 µl 20 mM , ß-mercaptoethanol 0.5 µl, 0.1 M and 
RNAsin (protection from RNAses) 0.25 µl, 40 U/µl, NX buffer 10x 1.5 µl was added and 
incubated at 37°C for 55 min. Then the mixture was incubated for 5 min at 95°C to inactivate 
the enzyme, and 90 µl H2O were added to the reaction. From the cDNA prepared, 2-3µl were 
used as template for the PCR reaction. 
 
II.2.3.4. RNA interference 
 RNA interference was performed with SilencerTm siRNA Cocktail Kit (RNaseIII) - 
Ambion. The purpose of our study was to knock down the B- and C-Raf genes by specifically 
degrading their mRNA. We designed primers and searched for a PCR spanning area, of 
around 400-500 bp, from the desired gene. The forward and reverse primers must contain tags 
of T7 promoters to be able to perform in vitro transcription (2-4 hrs) and produce dsRNA on 
the DNA template. After purification of the transcribed RNA it was digested with DNases (1 
hr at 37°C), and again purified. The dsRNA was then digested with RNase III (1 hr at 37°C), 
which produces the siRNAs. Thereafter we performed a new purification and quantified the 
yields of the siRNAs. For the transfection of the cells we used siRNA of a  final concentration 
of 100 nM. 
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For immunoprecipitation of cellular proteins, 20 µl sepharose was incubated with 0.5-
4 µg of antibody, 500-2000µg lysate and 300 µl IP buffer. Depending on the type of the 
experiment, lysates were additionally precleared with beads if background problems arose. 
Samples were incubated on a rotator for at least 2 hr at 4°C, and then washed with different 
wash buffers, depending on the stringency required. The washing buffer should insure low 
background and maximum preservation of complexed proteins. For example, when 
interactions between two proteins already known to have high interactions were analyzed, a 
strong wash buffer such as RIPA was used to reduce the background. When proteins with 
unknown interaction were evaluated, a mild washing buffer such as TLB Buffer was used in 
order to insure that interactions between the proteins of interest were not destroyed. The 
immunoprecipitated proteins were boiled in Laemmli buffer and subjected to SDS PAGE and 
Western blotting. 
 
II.2.4.2. Western blot 
Proteins separated on SDS-PAGE gels were transferred to a PVDF membrane using a 
wet transfer system with all components soaked beforehand in transfer buffer. The gel was 
placed on top of a piece of Whatman 3MM filter paper and sponge, overlaid with PVDF 
membrane, pre-washed in methanol, and equilibrated in transfer buffer. The blotting sandwich 
was completed by the addition of a second layer of filter paper and a sponge. The transfer in 
cassette assembly was carried out at 150 mA for 90 min. Following the transfer, the PVDF 
membranes were washed repeatedly in 1 x TBS/Tween-20 to remove any gel remnants. The 
remaining protein binding capacity of the gel was neutralised by incubation in blocking buffer 
for >1 h, under shaking. Excess blocking reagent was removed by washing 3 x with the 
appropriate washing buffer, before the membrane was incubated with the primary antibody 
diluted to the appropriate concentration in washing buffer containing 5 % BSA for 1 h at RT. 
The membranes were washed 3 x with washing buffer to remove the excess of the primary 
antibody. A peroxidase-conjugated, secondary antibody, specific for the isotype of the 
primary antibody used, was applied to the membrane at its correct working concentration, 
diluted in washing buffer containing 5 % BSA for 1 h at RT. Excess antibody was removed by 
washing 3 x with washing buffer. Protein-antibody complexes were detected on X-ray film 
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using a chemoluminesence reaction catalysed by the antibody-conjugated peroxidase. The 
ECL solution was used as substrate for this reaction, following the manufacturer’s protocol. 
 
II.2.4.3. Recombinant protein expression and purification 
 
 
II.2.4.3.1. Culture conditions and expression of TFPI protein 
Luria–Bertani (LB) broth medium was used to produce TFPI wild type and the mutant 
forms of the protein. 500 ml of LBamp (100µg/ml amp.) medium was inoculated with 10 ml of 
BL21 E. coli cells from an overnight culture. The mixture was shaken in an incubator at 37 °C 
and 190 rpm. When the culture medium reached an OD600 of 0.4, 50 µl of anhydrotetracyline 
was added to the cell culture to a final concentration of 2.0 µg/ml, in order to induce the 
expression of the recombinant protein. The cell culture was then incubated for additional 2 h 
at 25 °C for the synthesis of the protein. 
 
II.2.4.3.2. Purification of TFPI 
After incubation, the cell culture was centrifuged at 5000 rpm for 20 min at 4 °C to 
pellet the cells. The pellets were resuspended in 10 ml of pre-cooled buffer W, and sonicated 
under ice-cold conditions until lysis was complete. The suspension was then centrifuged at 
6,000 rpm for 15 min at 4 °C to remove the cell debris; the supernatant was additionally 
centrifuged in an ultracentrifuge at 35,000 g for 30 min at 4 °C to reduce the amount of total 
protein. After the centrifugation, the supernatant containing the TFPI protein was collected in 
a 50 ml Falcon tube. A chromatography column (0.8 x 4 cm) containing 2 ml Strep-Tactin II 
was initially washed with 10 ml of washing buffer at a flow rate of 0.5 ml/min. Then 10 ml of 
the supernatant containing the TFPI protein were loaded onto the column. Washing buffer 
(30 ml) was passed through the column to remove impurities. To elute the protein from the 
column, 7 x 500 µl of elution buffer was passed through the column. The eluent was collected 
(0.5 ml/tube). Thirty microliters of each fraction was analysed using a 1.5 mm 12% SDS–
polyacrylamide gel. The amount of protein was also quantified using UV spectrophotometry. 
To regenerate the column, it was first washed with 10 ml of washing buffer, followed by 
30 ml of regeneration buffer. Finally, 40 ml of washing buffer was run through the column to 
wash away the HABA. 
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II.2.4.4. Measurement of protein concentration (Bio-Rad protein assay) 
The Bio-Rad Protein Assay is based on an absorbency shift when Coomassie Brilliant 
Blue G-250 binds to the protein. Cell lysate containing 1-20 µg of protein was added to dilute 
Dye Reagent (1:5 dilution of Dye Reagent Concentrate in ddH2O). Mixing for 5-60 min the 
absorption was measure at a wavelength of 595 nm versus reagent blank (containing buffer 
only). 
 
II.2.4.5. Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS PAGE) 
Cells were collected, washed with ice-cold phosphate-buffered saline (PBS) and lysed 
in 50 µl of lysis buffer. The crude cell lysates were cleared by centrifugation. 5 µl 5x SDS-
loading buffer containing SDS was used to denature 20 µl of precleared cell extracts at 95° C 
for 5 min. SDS is an anionic detergent that disrupts nearly all noncovalent interactions in 
native proteins. ß-Mercaptoethanol is also included in the sample buffer to reduce disulphide 
bonds. The SDS complexes with the denatured proteins were then electrophoresed on a 
polyacrylamide gel in the form of a thin vertical slab. Vertical gels were set in between 2 glass 
plates with an internal thickness of 1.5 mm between the two plates. In this chamber, the 
acrylamide mix was poured and left to polymerise for at least 30 min at RT. The gels are 
composed of two layers: a 6-15% separating gel (pH 8.8) that separates the proteins according 
to size; and a lower percentage (5%) stacking gel (pH 6.8) that insures the proteins 
simultaneous entry into the separating gel at the same height. The separating and the stacking 
gels consisted of the following components: 
Separating gel   Stacking gel 
    Tris pH 8.8     2.5 ml.    1.25 ml 
    Acrylamide/bisacrylamide 29:1 (30%) 2.0-5.0 ml    1.7 ml 
    10% SDS     0.1 ml     0.1 ml 
    ddH2O      5.4-2.4 ml    6.8 ml 
    10% APS      0.1 ml     0.1 ml 
 
The separating gel was poured in between the two glass plates; a space of about 1cm 
plus the length of the teeth of the comb was left and isopropanol was added to the surface of 
the gel. After the separating gel was polymerised, the isopropanol was removed. The stacking 
gel was poured on top of the separating gel and a comb was inserted. The gel was left to 
polymerise. Then the samples were loaded in the wells of the slab and running buffer was 
added in the chamber. A cover was then placed over the gel chamber and 200 volts were 
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applied. The negatively charged SDS-proteins complexes migrate in the direction of the anode 
at the bottom of the gel. Proteins that differ in mass by about 2% can be distinguished with 
this method.  
 
II.2.4.6. Functional assays 
 
II.2.4.6.1. Xa formation 
 The functional activity of TF can be measured by the formation of factor Xa. The TF-
VIIa cleaves factor X either directly or indirectly via factor IX activation. The formed factor 
Xa cleaves the substrate S2222; thereby a product is formed that absorbs at 405 nm and can 
be measured photometrically. The blood coagulation factors were added in the form of the 
commercially available Beriplex that, besides the coagulation factors VII, X, IX and II, also 
contains the anticoagulant proteases antithrombin and protein C. Therefore, similar to the 
conditions in the blood not only the procoagulant, but also the anticoagulant components are 
included.  For the measurement of the procoagulant activity the isolated blood cells 
(neutrophils, platelets) were incubated for 10 min at 37° C. 
Afterwards, the samples were put in a 96 well plate to measure the OD in U/ml. In 
each measurement standard curves were prepared from recombinant TF. Subsequently to each 
well 50 µl 8 mM CaCl2 solution and 100 µl mixture of resuspension buffer, substrate S2222, 
and Beriplex (3.375 ml resuspension buffer, 400 µl S2222, 225 µl Beriplex) were added to the 
cell samples and the OD values were measured photometrically during 30 min in a ELISA 
reader. 
 
II.2.4.6.1.1. Platelets isolation 
Platelets were isolated from blood of healthy donors. The blood was drawn into 
sodium citrate (0.38% final concentration) and subsequently centrifuged at 130 x g for 15 min. 
The upper two thirds of the supernatant were supplemented with apyrase (0.2 U/ml). The 
suspension was centrifuged at 330 g for 10 minutes, and the platelet pellet was washed once 
with the platelet washing buffer, followed by an additional centrifugation at 330 g for 10 min 
and resuspended in the buffer of choice.  
 
II.2.4.6.1.2 Neutrophils isolation 
Human neutrophils were prepared by incubation of freshly obtained buffy coats with 
microbeads coupled to anti-CD15 antibodies for 15 minutes at 8°C. The suspensions were 
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thereafter applied on a selective column and washed 3 times with 2 column vol of antibody 
buffer. Then the column was transferred to a 15 ml falcon tube and the neutrophils were 
eluted with 1 column vol of antibody buffer.  
 
II.2.4.6.2. Thrombelastography 
 Currently, thrombelastography (TEG) is the most adequate method to measure the 
fibrin formation rate in whole blood and therefore allows functional examination of the blood 
coagulation system under conditions that are close to the in vivo situation. The principle of 
TEG depends on a stamp that is moving slowly forward and backwards in a small tube 
containing the blood. If a stimulus induces the formation of fibrin polymers, the movement of 
the stamp is reduced by the formed clot, which is registrated by a detection system and 
indicated in a graphic form. The fibrin formation rate represents the coagulation time (CT). 
Further parameters of the measure are thrombus growth rate, or clot formation time (CFT).  
Blood was collected in a syringe with citrate (1/10 of the blood volume) and corn 
trypsin inhibitor was added (CTI 32 µg/ml, inhibitor of the intrinsic coagulation pathway). 
Then, 300 µl of blood were pipetted into a TEG tube and collagen (12 µg/ml) and the 
different TFPI variants were added. By addition of 60 µl of a 100 mM CaCl2/10 mM HEPES 
solution, the coagulation process was started. The addition of activators or inhibitors was 




III.A. Raf proteins and their role in endothelial maturation 
III.1. B-Raf is critical for vascular development 
 A large number of molecules regulate distinct steps in vascular development such as 
vasculogenesis, angiogenesis, remodeling and maturation of the blood vessels. Wojnowski et 
al. (1997) found that the serine-threonine kinase B-Raf is critical for the proper formation of 
blood vessels. B-Raf knock out embryos die between d 10-12, suffering from extensive 
hemorrhages due to enlarged and ruptured vessels (Fig. 3-1 panels a, c & d). Further analysis 
revealed that knock out mice had apoptotic mature endothelial cells and higher number of 
progenitor cells embedded within the embryonic tissues. Studying this phenotype in more 
detail and comparing electron microscopy pictures of knock out and wild type embryos, 
Hatzopoulos et al. (unpublished data) found differences within the structure of the vessel wall, 
characterized by reduced collagen fibers and malformed peri-vascular structures (Fig. 3-1 
right panels b). These findings prompted us to investigate the role of B-Raf in the 
differentiation of endothelial progenitor cells to better understand the molecular basis of this 
phenotype. 
Wild Type B-Raf Knock Out
Wojnowski et al., Nat.Genetics 1997 Hatzopoulos et al.
b
 
Figure 3-1 The B-Raf knock out is lethal at day 10.5 of the embryonic development of the mice and has 
a vascular phenotype characterized with reduced amounts of collagen in the vessel wall, enlarged and ruptured 
vessels leading to hemorrhages in the body cavities. 
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Based on a previously established method (Hatzopoulos et al. 1998), we isolated 
embryonic endothelial progenitor cells (eEPCs) at d 7.5 from the preendocardial tubes of 
mouse embryos. It was earlier found that these cells exhibit stem-cell like unlimited 
proliferation and are able to differentiate into a mature endothelial phenotype upon treatment 
with retinoic acid and cAMP (Hatzopoulos et al. 1998). We analyzed the expression of a set 
of genes potentially induced upon differentiation of the eEPCs. These include early 
endothelial markers such as Tie-2, thrombomodulin and VGFR-1, which characterize these 
cells as part of the endothelial lineage. 
 
 
Figure 3-2 cAMP leads to differentiation of the eEPCs, influencing specific genes involved in the 
process. RT-PCR analysis using gene-specific primers reveals that a subset of endothelial markers are expressed 
in eEPCs (e.g., Tie-2, thrombomodulin, VEGFR-1), while others are induced upon differentiation (e.g., vWF, 













III.2. Gain of function of B- and C-Raf in embryonic endothelial progenitor cells  
 
III.2.1. Preparation of constructs for induction of constitutively active Raf proteins 
 
We created constructs containing the hormone binding site of the estrogen receptor 
fused to the kinase domain of the B-Raf or C-Raf proteins using standard molecular biology 
techniques. By applying or removing estrogen from the culture medium, the fusion molecule 
was expressed, it was bound by heat shock proteins (HSP90) and kept in an inactive state in 
the cytoplasm of the cells, until an estrogen molecule associates with the hormone binding site 
of the estrogen receptor. This type of constructs gave us the opportunity for switching on and 
off the activity of both kinases. Estrogen receptor binding changes the conformation of the 
fusion molecule, the HSP90 molecules are released, allowing the functional activity of the B- 
and C-Raf kinase domains. Figure 3-3 shows a schematic drawing of the B- and C-Raf fusion 
constructs and their mode of activation.  Both constructs were cloned in vectors containing a 
PGK (phosphoglycerol kinase) promoter, known to be highly active in the eEPCs.  
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Figure 3-3 Constructs for B-Raf and C-Raf fused to the hormone binding domain of the estrogen 
receptor. Panel A represents the structure of the constructs under the PGK promoter and containing a polyA site 
in the 3’ ends. The start and the terminal amino acids in the hormone binding site of the estrogen receptor and the 
kinase domains of B- and C-Rafs are marked with letters. Panel B depicts a schematic drawing of the Raf 
domain activation upon estrogen stimulation.  
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The transfection efficiency of the eEPCs was high, with values of over 90%. That 
allowed us to work with approximately homogeneous cell lines in every experiment. Figure 3-
4 shows a typical transfection experiment of eEPCs with the reporter EGFP gene under the 
control of the PGK promoter. The intensity and the amount of the EGFP indicates that the 
experimental system is suitable for the projected experiments.  
 
   
Figure 3-4. The eEPCs exhibit a high transfection efficiency (>90%). The PGK promoter is highly 
active as indicated by the strong expression of the reporter EGFP gene (the cells were ~80% confluent, in green 




III.2.2. Establishment of stable eEPC lines with constitutively active B- and C-Raf 
 
To obtain stable lines expressing the B- and C-Raf fusion constructs, we used 
electroporation as the transfection method and employed the neomycin antibiotic G418 for 
selection. The constructs were shown to be integrated into the genomic DNA (Figure 3-5a 
panel A) and expressed as mRNA (Figure 3-5a panel B). The PCR primer pairs used spanned 
a unique region of the ER and the kinase domains of B- and C-Raf. Then single positive 













Figure 3-5a. Verification of DNA integration (panel A) and mRNA expression (panel B) of the fusion 
constructs between the hormone binding site of the estrogen receptor and the kinase domains of Raf proteins. 
With – and + are indicated the non transfected (mock) and transfected cells. M is the marker, and C represents 
the positive control, where the plasmid with the construct was used a as template for the PCR.  
 
 
 To prove the expression of the fusion molecules on the protein level, we used 
immunoprecipitation (IP) and western blot techniques. Using different antibodies directed 
against the estrogen receptor and the carboxyl terminus of Raf proteins, we indeed verified the 














 Figure 3-5b.Fusion proteins are properly expressed in eEPCs. B- and C-Raf parts of the molecules were 
detected by an IP with an anti-ER antibody followed by western blot with antibodies that specifically recognize 
the kinase domains of B- and C-Raf. In complementary fashion, the same proteins were detected by IP with the 
B- or C-.Raf antibodies followed by western blotting with the anti-ER antibody. 
 
 The first downstream partners in the signaling pathway of the Raf proteins are 
MEK1/2, which in turn phosphorylate the ERKs, capable of translocating to the nucleus and 
to influence the transcriptional activation of target genes. To test if the fused proteins were 
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functional, we examined the phosphorylation of MEKs after estrogen stimulation. eEPCs 
were transiently transfected with the constructs and the empty vector (mock transfection) 
using Lipofectamine2000. Some of the cells were grown for 12 hours in nutridoma (a 
starvation medium without any mitogens to reduce MEK phosphorylation) after the 
transfection (Fig. 3-6 lanes 3, 4, 7, 8) and then induced with estrogen (Fig. 3-6 lanes 1, 3, 5, 
7). Using MEK antibodies, we found expression of the MEK's in all samples with some 
variations (Lanes 1 to 8 in panel A). However, using specific phospho-MEK antibodies 
recognizing only the phosphorylated forms, we detected them only in the estrogen-induced 
samples transfected with the Raf constructs. Mock transfected, starved and estrogen induced 
cells were negative, demonstrating that the fusion constructs were active only after estrogen 
stimulation (Fig. 3-6, compare lane 3 with lane 7).  
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 Figure 3-6 Functional kinase assays document that the constructs are transmitting the signal to their 
downstream partners MEK only after estrogen stimulation. Panel A western blot with MEK antibody shows the 
expression levels of MEKs in the eEPCs. Panel B western blot with phospho MEK antibody presents the 
phosphorylated forms of the MEKs. The lower molecular weight band represents a non-specific recognized 





III.2.3. Effects of inducible B- and C-Raf activation in eEPCs 
 
III.2.3.1. Effect on eEPC proliferation 
 
B-Raf and C-Raf are engaged in the regulation of proliferation in many cell types 
(Smalley et al. 2004). To identify their functional effects, we performed proliferation assays in 
eEPCs transfected with B-Raf and C-Raf inducible constructs and EGFP constructs as 
negative controls. The samples were transfected and part of them induced for 8 hours with 
estrogen. The cells were then allowed to grow for 48 hours and counted. From the results 
presented in Fig. 3-7, it can be deduced that in the C-Raf transfected and estrogen induced 
cells, the cell numbers were almost doubled compared to the non-estrogen treated samples. B-
Raf also slightly increased the cell numbers. EGFP-transfected cells with or without estrogen 
served as control, verifying that estrogen application alone did not influence cell proliferation.
 































































 Figure 3-7. C-Raf markedly increases proliferation of eEPCs while B-Raf has a moderate effect. Data 




III.2.3.2. Effect of Raf kinases on the differentiation of eEPCs 
 
 To further explore the effects of B-Raf and C-Raf on the differentiation of eEPCs, the 
cells were transfected with the constructs as described above. After 8 hours induction we 
isolated RNA and prepared cDNA. The cDNAs were then used as templates for the PCR 
analysis, using a set of gene-specific primers. The genes analyzed included the house keeping 
aldolase gene as control, and genes expressed and induced in eEPCs upon differentiation with 
cAMP, such as Flk-1, vWF, thrombomodulin, P-selectin, and M-CSF. Upon transfection with 
both B- and C-Raf constructs, the expression of all of the mentioned differentiation markers 
was elicited (Fig. 3-8, lane 7, 11) at the same level as by cAMP treatment.  From these 
experiments, we concluded that the kinase domains of B-and C-Raf are different in 
stimulating the proliferation, but can substitute for each other in the induction of the 
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Figure 3-8. B-Raf and C-Raf kinase domains have similar effect on the differentiation of the eEPCs. 
RT-PCR analysis using gene-specific primers reveals that a subset of endothelial markers including Flk-1, 
Thrombomodulin, P-selectin, M-CSF are upregulated under B- and C-Raf activation with estrogen. Lane 7 and 
11 show the stimulation of the differentiation after the induction of B- and C-Raf respectively, aldolase being 
used as a loading control.   
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III.3. Loss-of function experiments with B- and C-Raf in eEPCs 
 
To further elucidate the differential function of B-Raf and C-Raf in eEPCs, we 
investigated the effects of B-Raf and C-Raf deficiency on the proliferation and differentiation 
of the eEPCs. To this purpose, we knocked down the expression of both molecules in eEPCs, 
using the recently developed technique of RNA silencing by double stranded small inhibitory 
RNAs. The SilencerTm siRNA Cocktail Kit (RNaseIII) - Ambion was employed in all 
experiments. Because of the high structural similarity between the two Raf family proteins, it 
was important to use siRNAs prepared from areas of no or very low homology. Alignment of 
B-Raf and C-Raf gene sequences indicated that the 5´untranslated areas of the two genes 
exhibit substantial differences. Therefore, we designed primers for this part of the gene and 
the PCR-amplified products were used as templates to prepare siRNA cocktails specific for 
murine B- and C-Raf. 
 With the optimised dsRNAs we performed transfection of eEPCs using oligofectamine 
as vehicle for 48 hours. Then we tested the specificity of our RNA mixtures by isolating total 
RNA. The RNA samples were used to synthesize cDNA and analysed by PCR with specific 
primer pairs for B-Raf and C-Raf. The results in figure 3-9a show that each cocktail 
specifically reduced the mRNA levels of its gene of origin, but had no effect on the expression 
level of the other Raf gene. Aldolase was used to control for equal loading.  
 We also observed that cAMP differentiation did not interfere with the silencing 





 Figure 3-9a. Silencing of the mRNA expression for B-Raf and C-Raf by RNAi was successfully 
performed in eEPCs, since there is no interference of the B-Raf siRNA with the C-Raf expression and viceversa. 
 
 
 Using a Scicon densitometric program, we quantified the differences in the mRNA 
expression levels before and after the B- and C-Raf knock-down. Figure 3-9b shows that for 
B-Raf we achieved a 3-fold reduction in the RNA levels, while for C-Raf the reduction rate 
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 Figure 3-9b. Densitometric quantification of the mRNA expression levels after RNAi treatment 
indicates ~3-fold reduction of B-Raf mRNA levels and ~2 -fold lowering for C-Raf. All results were equalized 
using aldolase mRNA levels. Column 1-Oligofectamine treated cells; 2 and 3-B-Raf si RNA treated cells; 4 and 
5-C-Raf si RNA treated cells; 6-Untreated cells.  
 
 
In a next step, we checked the effects of the RNAi induced silencing on the expression 
of the B-Raf and C-Raf proteins. To this purpose, we performed experiments using eEPCs 
transfected for 72 hours with oligos for B-Raf siRNA and C-Raf siRNA in two repeats each, 
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and then made immunoprecipitations (IP) and western blots with specific antibodies, 
recognising the B-Raf isoforms and C-Raf. The results are presented in figure 3-9c. B-Raf 
protein is present with two splice variants in eEPCs, with molecular weights of 94 kDa and 68 
kDa. Panel A of the figure shows that both B-Raf isoforms were significantly reduced after 
treatment with the B-Raf siRNAs, while at the same time the C-Raf-specific siRNAs had no 
effect on B-Raf, further supporting their specificity. The stronger reducing effect of the RNAi 
at the protein level compared to the mRNA expression may be due to the fact that RNA 
interference not only leads to mRNA degradation, but also blocks mRNA translation.  
We performed parallel experiments using the C-Raf siRNAs, followed by IP/Western 
blot for detection of the C-Raf protein. The extend of reduction was also pronounced and 
specific for C-Raf, since the B-Raf siRNA oligos did not interfere with the C-Raf expression.  
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 Figure 3-9c.  The B- and C-Raf proteins were efficiently down-regulated with RNAi in eEPCs, as 
proved by western blotting using specific B- and C-Raf antibodies. The unspecific lower molecular weight band 






III. 4 Silencing of B-Raf and C-Raf has different functional effects in eEPCs 
 
 To explore the effects of the RNAi on the proliferation and differentiation of eEPCs, 
we performed similar experiments as with the above mentioned gain-of-function approach 
using the inducible constructs for B- and C-Raf (III.2).  
 First, we examined the effects of B- or C-Raf knock-down on the proliferation rate of 
the eEPCs. For this purpose, we split the cells in two equal amounts each in three repeats, and 
transfected them with RNAi oligos for B- and C-Raf for 72 hours. The controls were just 
treated with oligofectamine for the same time period. Then, we detached the cells with EDTA 
and counted them using a Coulter counter. The results are presented in Fig. 3-10. We found 
that RNAi treatment for both B- and C-Raf impaired the growth of the cells. The effect was 
somewhat stronger in cells transfected with siRNA oligos for C-Raf. This was consistent with 
the observations of the gain-of-function experiments using the inducible constructs, where C-
Raf was more efficient in inducing eEPC proliferation. 





















 Figure 3-10. C-Raf knock-down suppresses the proliferation of eEPCs. Specific reduction of B-Raf 
mRNA has a similar, but more moderate effect. Data are mean ±SD, n=3. 
 
 
We then investigated whether the RNAi for B- and C-Raf had an influence on the 
differentiation of the eEPCs. In Fig. 3-11, the results are presented from a representative 
experiment, where we transfected eEPCs with siRNAs for B-Raf, C-Raf, or oligofectamine 
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treated cells for 72 hours. During the last 8 hours, one of the two samples was induced by 
cAMP and at the end of the experiment, RNA was prepared by standard isolation protocols 
and processed for cDNA preparation. Using the same primers for the set of genes we analyzed 
above in the gain-of function approach, we performed PCR to evaluate whether the reduced 
levels of the B- and C-Raf proteins would influence the differentiation of the eEPCs. In figure 
3-11 results are shown in which cAMP was employed to induce the differentiation process in 
the oligofectamine control treated and C-Raf transfected with siRNA (lanes 2 and 6 Fig.3-11). 
Differentiation was indeed abrogated in the B-Raf siRNA oligos transfected cells (Fig. 3-11 
lane 4). This indicates that B-Raf and not C-Raf is required for the cAMP-mediated eEPC-
differentiation. When comdined, the gain- and loss-of-function experiments indicate that B-
Raf and C-Raf kinase domains can compensate for each other in their kinase activities. 
Moreover B-Raf appears to be more engaged in the process of differentiation. In addition, 
while both B- and C-Raf stimulate proliferation of the eEPCs, C-Raf is a more potent 
activator of this process.  
Thrombomodulin













 Figure 3-11. B-Raf knock-down ablates cAMP-mediated eEPC differentiation, while silencing of C-Raf 
has no effect on this process. RT-PCR analysis using gene-specific primers reveals that the endothelial genes 
Flk-1, Thrombomodulin, P-selectin, M-CSF, vWV are differentially regulated under conditions of B- and C-Raf 
knock down. Aldolase was used as a loading control. 
Results 65 
 
To further corroborate this conclusion, we isolated eEPCs from mouse embryos, 
deficient for B-Raf. B-Raf knockout mice are lethal at around d 10-12, therefore isolation of 
eEPCs at d 7.5 was feasible, as determined by genotyping of the respective eEPC clones. We 
then performed the differentiation experiment with cAMP and retinoic acid and compared the 
results between wild type and B-Raf null cells. RT-PCR confirmed the data described above. 
Importantly, B-Raf null cells failed to differentiate, corroborating the key role of B-Raf in the 



















 Figure 3-12. B-Raf knock out eEPCs do not differentiate, as indicated by the inability of cAMP to 






III.B. Role of the endothelium in the coagulation start 
 
 TFPI which is mainly expressed in endothelial cells is the major anticoagulant 
molecule in the context of the initiation of blood coagulation. TFPI is known to be degraded 
by different types of proteases, such as HNE, Cathepsin G, different types of MMPs, and 
others. The main goal of our study was to analyze weather the proteolytic cleavage of TFPI 
was of relevance for his anticoagulant properties. 
 
III.5. Expression and purification of human TFPI  
Using standard molecular biology techniques, we cloned TFPI in the pASK-IBA3 
vector, which allowed us to express the recombinant protein in sufficient amounts and to 
purify it using a Strep-tag system. This system is known to provide a high purity level of the 
recombinant protein. The different elution fractions of the expressed TFPI were detected by 
western blotting, using a specific antibody recognizing the C-terminal part of the protein (Fig. 
3-13). 
 
1        2        3        4
Elution fractions with purified TFPI  
 Figure 3-13. Recombinant TFPI was expressed and purified using the Strep-Tag system. An anti-TFPI 
antibody against the C-terminus was used to verify the expression. 
 
 
III.6. Site directed mutagenesis of human TFPI 
 In order to modify the cleavage site of TFPI for HNE, Threonine (T) in position 87 
was substituted by Phenylalanine (F). HNE is expressed in high amounts on the surface of the 
neutrophils, which get in contact with the endothelium upon vascular injury. In a next step, 
this mutant was employed to change two further proteolytic sites. The leucine (L) in position 
21 recognized by MMP9, was substituted by alanine (A). In addition, leucine (L) in position 
89 recognized by Cathepsin G, was also changed into alanine (A) (Fig 3-14). We then 
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obtained three mutated TFPI forms (T87F, T87F/L21A, and T87F/L89A), together with wild 




 Figure 3-14. DNA sequences analyses verify the correct structure of the TFPI mutants prepared. 
 
 
III.7. Functional tests with the recombinant human TFPI and its variants 
 To check the functionality of the recombinant proteins prepared, we performed 
functional tests including limited proteolytic digestion experiments, formation of factor Xa 
(procoagulant activities), and thrombelastography. We quantified and equalized all the 
isolated proteins and then started the experiments.  
 
III.7.1. Limited proteolytic digestion in vitro  
 
 We first analyzed whether the different mutated TFPI molecules were indeed resistant 
against the proteolytic digestion by the different proteases. The recombinant native protein 
and the mutated forms were digested with the serine proteases HNE, MMP-9, and Cathepsin 
G. The reactions were performed at 37°C for five to ten minutes and assayed on the western 
blot using a polyclonal TFPI antibody. All the mutated TFPI forms showed a delay in the 






 Figure 3-15. The indicated TFPI mutants (5 µg), and the wild type TFPI (5 µg), were digested with 
serine proteases and with MMP-9 (at concentrations of 10 nM for HNE, 50 nM for CathepsinG and 200 nM for 
MMP-9). Compared to the native protein, TFPI degradation is delayed after specific substitution of the amino 
acids at the proteolytic cleavage sites (w.t.- wild type). 
 
 
III.7.2. Procoagulant activity 
 
 To evaluate the functional behaviour of the different mutated forms, we determined 
the formation of factor Xa in the presence of platelet/neutrophil suspensions. When incubated 
with neutrophils, platelets rapidly cleave factor X. It has been hypothesized that this is due to 
proteolytic inactivation of TFPI (Engelmann et al., 2003). 
 We therefore added the native TFPI and the mutated forms of the protein to 
suspensions consisting of platelets and neutrophils. The results are presented in Fig 3-16. 
Native TFPI reduces the procoagulant activity by around 30%, while the mutated forms lower 
the factor Xa formation by 40% to 60%. The strongest effect was observed with the double 






















 Figure 3-16. Factor Xa formation experiments in suspensions of platelets and neutrophils indicate that 
the initiation of coagulation is delayed by mutations of the proteolytic cleavage sites of TFPI. P-platelets, P/N- 
platelets-neutrophils suspension, nTFPI- native tissue factor pathway inhibitor and its mutant forms were 
incubated in platelets-neutrophil suspension. The recombinant TFPI proteins were used at 2.5 nM (end 
concentrations). Data are mean ±SD, n=5. 
 
 
III.7.3. Thrombelastography  
 
 To address whether the TFPI mutants affected the formation of fibrin was assessed 
whole blood. As a control, we used total blood without collagen (Fig 3-17, panel I). In panel 
II, blood was activated by collagen (12µg/ml) in the absence of TFPI. In panel III native TFPI 
was included into the blood, while in panel IV the T87F/L89A mutant was added. The results 
indicate that the inhibition of fibrin formation elicited by the native TFPI is strongly enhanced 
(by about 3-fold) when the HNE and Cathepsin G cleavage sites are mutated, preventing the 









 Figure 3-17. Determination of fibrin formation in anticoagulated blood system revealed that the 
T87F/L89A TFPI mutant delays fibrin formation more efficiently, than the native TFPI. The distance between 
the starting point and the broadening of the amplitude represents the fibrin formation.The horizontal line of the 
rectangle corresponds to 600 sec. I-total blood without collagen, II-blood activated by collagen (12µg/ml), III-
native TFPI added into collagen activated blood, IV-mutated TFPI added into collagen activated blood. All the 





IV.1. B- and C-Raf in endothelial maturation 
 
 During the last few years, considerable progress has been made towards elucidating 
the mechanisms indicating the transition of the endothelial progenitor cells to mature 
endothelial cells. Moreover, the functions and the possible applications of EPCs as therapeutic 
agents have been described. Knowing in more detail the signal transduction pathways 
modulating gene transcription and the ensuing endothelial progenitor cell response will give 
us an opportunity to influence endothelial cell development and activation.  
Until now, little is known about the role and the regulation of the MAPK kinase signal 
transduction pathway in endothelial progenitor cells. One reason is that adult EPCs are 
difficult to isolate and maintain in cell culture.  Hatzopoulos et al. (1998) established a stable 
cell line from mouse embryonic endothelial progenitor cells (eEPCs) that arise on E 7.5 at the 
onset of vascular development and formation of the cardiovascular system. Working with 
mouse eEPCs could be of relevance and also a good model system for styding how the 
process of maturation is occuring in human embryonic endothelial progenitor cells, which 
from an ethical point can not be researched.  The eEPCs possess specific features of immature 
endothelial cells, including expression of endothelial-cell specific markers such as 
Thrombomodulin and Tie-2. Under in vitro conditions, the cells can be induced to 
differentiate with cAMP. This process results in the activation of a set of genes specific to the 
endothelial lineage, i.e., Flk-1, vWF, P-selectin, M-CSF, and others, proving a novel system 
to study the transition of the eEPCs to the mature endothelium. This differentiation process is 
probably regulated by a variety of signaling mechanisms. In this work, we have shown that 
one of the key components in the regulation of the maturation process is the B-Raf kinase, a 
member of a larger family comprising A-Raf, B-Raf and C-Raf. The role of these proteins in 
the embryonic development was addressed by the work of Wojnowski et al. (1997), preparing 
B- and C-Raf knock out mice. The B-Raf KO mice are subjected to embryonic lethality 
around d 10-12. One of the most relevant structures affected by the absence of the B-Raf 
protein are the blood vessels and the endothelial cells. C-Raf KO mice die within hours after 
birth, because their lungs fail to inflate. They show general growth retardation and defects in 
placenta, skin, and lungs. 
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The Raf family proteins are crucial units in the “normal” cell life of every cell and 
even single mutations in their structures disorganize and transform cellular function. For 
example, B-Raf mutations were identified in human lung adenocarcinoma (K438T), lung 
small cell carcinoma (T439P), malignant melanoma (K438Q), colorectal tumors (V599E) and 
others. (Mercer et al.2003; Davies, Bignell, Cox et al. 2002). The Raf family proteins are 
relatively well studied components of the cell signaling pathways in different cell types and 
species (Hagemann and Rapp 2000, O’Neil and Kolch 2004). In PC12 cells all three forms of 
the Raf family are expressed. These cells proliferate under EGF stimulation, but differentiate 
into a neuronal like phenotype after treatment with NGF. Both growth factors are able to 
activate Raf isoforms. Wixler et al. (1996) investigated whether there are differences in the 
activation kinetics of A-Raf, B-Raf, and C-Raf in response to EGF and NGF treatment. An 
initial activation of all three kinases was detected, but only A- and B-Raf showed sustained 
activation by NGF, which was not seen after EGF treatment. 
 The process of regulation of the Raf family member requires protein-protein 
interactions, phosphorylation, and presumably lipid binding (Slupsky et al. 1998). It was 
proposed that Raf dimerization also might be involved in the activation (Masson et al. 1999). 
The initial Raf activation requires the small G-protein Ras, but the following sustained 
activity of B-Raf is mediated by another small G-protein, Rap1 (York et al. 1998) (Fig. 4-1). 
   
 
Figure 4-1. Schematic drawing of the Ras/Raf/Erk signal transduction pathway in eEPCs. 
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 In PC12 cells comparison of cAMP sensitivity of C-Raf and B-Raf showed functional 
differences between the two isoforms (Erhardt et al. 1995). While C-Raf activity is blocked by 
cAMP, B-Raf is activated (Ohtsuka et al. 1996). cAMP-induced PKA phosphorylates Rap1, 
which not only blocks C-Raf activation, but binds to B-Raf, resulting in sustained activation 
of this kinase and concomitant differentiation of PC12 cells (Vossler et al. 1997) (Fig 4-1). 
This regulatory system has also implications for differential responses of cell types in the 
brain (astrocytes and neuronal cells) to cAMP. Central nervous system-derived neurons, but 
not astrocytes, express B-Raf in addition to C-Raf. In neurons cAMP activates Erk in a 
Rap1/B-Raf dependent manner, while in astrocytes cAMP decreases Erk activity by inhibition 
of C-Raf. Thus, B-Raf appears to be the molecular switch, which causes differential 
regulation of Erk in neurons versus astrocytes in response to cAMP (Dugan et al. 1999). This 
pathway is driven in an opposite way in renal epithelial cells, where the cAMP regulated 
proliferation is depending on B-Raf, but not on C-Raf (Yamaguchi et al. 2004). 
 
IV.1.1 B- and C-Raf function upon regulated overexpression 
 
Based on the observations in neuronal and other cell types, and the vascular-specific 
phenotype of the B-Raf KO mice, we investigated the influence of the B-Raf and C-Raf 
proteins on the proliferation and differentiation of eEPCs. To accomplish this goal, we 
prepared molecular tools for gain- and loss-of-function experiments.  The gain-of-function 
constructs for B-Raf and C-Raf function were designed to allow an inducible system, where 
we could obtain regulated activation of the kinase domains of either protein by estrogen 
treatment. The influence of estrogen itself on the eEPCs was checked before the start of the 
experiments, confirming that the hormone alone had no influence on the outcome of our 
experimental procedures. 
 A second major goal of our work was to reveal the link between cAMP stimulation 
and the functions of the Raf proteins in the eEPCs. The high transfection level of the eEPCs 
was an important precondition for performing all our experiments successfully. In optimizing 
the conditions, we found that the promoter which drives expression in eEPCs is of great 
importance. With the use of the standard CMV promoter, no satisfying amounts of proteins 
were obtained. For this reason we chose to use vectors containing the PGK (phosphoglycerol 
kinase) promoter, which has found to be strong enough for the production of the protein 
variants in the eEPCs. 
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 We not only proved that the expression levels of the proteins were sufficiently high, 
but also showed that the produced proteins were functional and capable of phosphorylating 
their downstream partners in the signaling pathways. We performed kinase assays after 
starvation in media without FBS (the main source of growth factors and inducers of the 
MAPK pathway) thus depleting the cells from any extra cellular signals activating the MAPK 
pathway. Indeed, the fusion proteins successfully phosphorylated their immediate downstream 
partners MEK1/2 after estrogen application. By using antibodies that specifically recognized 
phospho MEK, we documented that activation of the MEKs depends solely on the treatment 
with estrogen.  
 Then, we analyzed the functional responses of the eEPCs after triggering the B- and C-
Raf activities. The already established knowledge about cAMP differentiation was the starting 
point for our experiments. We could show that the activation of the kinase domain of B- and 
C-Raf leads to the upregulation of genes involved in the differentiation of the eEPCs, as for 
example vWF, thrombomodulin, M-CSF, P-selectin, Tie-1, which are not expressed in the 
progenitor cells. The effect of this activation led us to conclude that both B- and C-Raf kinase 
activities are sufficient to reconstitute the cAMP -induced differentiation of eEPCs.  In 
contrast, loss of function experiments (discussed below) revealed that the B-Raf protein alone 
is necessary for the differentiation of the EPCs. We conclude that the regulatory CR1 and 
CR2 domains of the Raf proteins are necessary to achieve specificity and that either kinase 
domain of B- or C-Raf can substitute for each other. 
 A further scope of the experiments was to investigate the effects of Raf proteins on the 
proliferation potential of the eEPCs. For this purpose, we used the B- and C-Raf constructs 
(and control EGFP-containing construct), which were transfected into eEPCs and induced. 
The results showed that C-Raf is a more potent activator of the proliferation of the eEPCs than 
B-Raf. This result is consistent with previous results observed in neuronal cell lines, where C-
Raf was linked to proliferation and B-Raf to NGF-mediated differentiation (Kao et al. 2001). 
It is known that just C-Raf but not B-Raf is interacting with Cdc25 phosphatases which play a 
key role in cell-cycle progression by triggering activation through the removal of inhibitory 
phosphate groups of the cyclin-dependent kinases (CDK) (Nilsson et al. 2000). The 
phosphorylation of Cdc25 by C-Raf may serve as a possible link between mitogenic signaling 




IV.1.2 B- and C-Raf roles into eEPCs in condition of knock down 
 
The technique of RNA interference has recently been developed for the reversible 
down regulation of gene expression. Using this method, we investigated the role of both B- 
and C-Raf from another aspect, namely knock down or loss-of-function of Raf genes in 
eEPCs. The three proteins of the human Raf family have a similar type of organization and 
high levels of homology in between each other. They consist of three conserved regions, 
namely CR1, CR2, and CR3, connected between each other by linker areas. The amino-
terminal regulatory domain contains the conserved regions CR1 and CR2, while the carboxy-
terminal kinase domain constitutes the third conserved region, CR3. B-Raf shows a 75% 
homology to A-Raf and a 65% homology to C-Raf in the CR1 region, where the RBD (Ras 
binding domain) and CRD (cysteine-rich domain) are located. The serine/threonine rich CR2 
region has a 47.6% homology with both A-Raf and C-Raf. In the CR3 region, the homology is 
higher, accounting to 76.4% with A-Raf, and 79% with C-Raf. The first 30-40 amino acids of 
the amino terminus and the last 20 amino acids of the carboxy terminus differ considerably 
among the various isotypes. Overall B-Raf shows 52% homology to A-Raf and 54% 
homology to C-Raf (Sithanandam et al. 1990). The Raf family proteins can be generally 
divided into two functional domains. When projecting the RNAi experiments in order to 
obtain isoform specific effects, it was important to find well distinguishable non-homologous 
areas in between the three proteins. This was done successfully, as the results showed specific 
down regulation of the respective mRNA and protein levels. The siRNA oligonucleotides 
chosen, corresponded to regions encompassing the 5’ ends of the molecules including parts of 
the untranslated and coding regions, which ensured complete degradation, precluding the 
formation of any truncated forms through differential splicing. Using the RNAi kit we 
obtained strong reductions of the mRNA levels of both B-Raf and C-Raf. Indeed, compared to 
mock transfected cells, an approximately 100% suppression of the B-Raf protein levels and 
around 80% of the C-Raf contents was achieved. The results can be explained by the 
canonical mechanism of RNA interference (degradation of mRNA) and by the additional 
effect of the siRNAs on promoting the process of mRNA degradation and simultaneously 
blocking mRNA translation. The knock down levels of any protein cannot be really predicted 
and the success in the method depends mainly on the specificity of the cell type, the efficacy 
of the siRNA cocktail and the particular mRNA features (secondary structure, stability), also 
of the protein turnover in the cell. Once having established appropriate siRNA tools, we 
analyzed the proliferation rates and the cAMP-induced differentiation on the eEPCs. Our 
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results indicated differential roles for the B-Raf and C-Raf proteins in the processes of 
differentiation and proliferation. While cAMP treatment of eEPCs turns on differentiation 
under control conditions, in the case of the B-Raf knock down the process was blocked. When 
we tested the same set of genes already analyzed for the evaluation of the kinase domain 
functions of the two proteins, however, none of the genes was induced. The knock down of C-
Raf in the eEPCs had no effect on the differentiation, and showed induction levels comparable 
to the mock-transfected cells. These results were confirmed in B-Raf null eEPC clones 
established from the corresponding KO mice. It is noteworthy that the differential role of the 
B- and C-Raf kinases in the eEPC proliferation revealed in the gain-of-function studies was 
also confirmed in the loss-of-function approaches, since knock-down of C-Raf had a more 
pronounced effect on eEPC proliferation than B-Raf. 
The results thus allow a first insight into the molecular mechanisms that drive growth 
and differentiation of eEPCs. It is known that cAMP has a dual and opposite effect on C-Raf 
versus B-Raf, influencing both molecules through protein kinase A (PKA). PKA 
phosphorylates the small G protein Rap1, which in turn blocks C-Raf, which at the same time 
can act as a sustained activator of B-Raf. In parallel, PKA phosphorylates B-Raf on its own, 
which has an activation effect as well. Our data are consistent with this scenario, since we find 
that B-Raf is necessary and sufficient to transmit the cAMP-mediated differentiation signal, 
while C-Raf appears to be dispensable. 
The findings in eEPCs might have broader implications in the overall field of vascular 
biology. The genes specifically induced by the B-Raf kinase in eEPCs have also important 
roles under pathophysiological conditions. For example, while thrombomodulin and vWF are 
involved in coagulation, P-selectin is critical for the homing of cells of the immune system at 
sites of inflammation, and Flk-1 participates in angiogenesis. Controlling the expression of 
these genes via modulation of B-Raf could open new ways to manipulate their function. 
As discussed above, C-Raf has an important role in eEPC proliferation. The results 
showed that growth rate reduction was stronger in cells transfected with C-Raf siRNA oligos 
as compared to mock transfected and B-Raf siRNA transfected cells. These results confirmed 
data obtained with the inducible expression of B-Raf and C-Raf. We conclude from the 
proliferation experiments that the eEPCs proliferation is considerably more dependent on C-
Raf compared to B-Raf. This finding could assist in finding new tools to preferentially modify 
endothelial cell growth (a critical process in pathological angiogenesis), while at the same 
time preserving the ability for stimulation of the mature endothelial cells.  
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Figure 4-2 presents a schematic drawing of the roles of B-Raf and C-Raf in the 
processes of differentiation and proliferation of the eEPCs. The decision which pathway is 
activated depends on the incoming extracellular mitogenic stimuli and the strength of 
activation. The proteins may be considered as signal collectors that further propagate the 
incoming signals to their downstream partners (MEKs and ERKs). Thereby, the activities of 







Figure 4-2. The roles of B-Raf and C-Raf in the proliferation and differentiation of eEPCs as revealed by the  
findings of the present investigation. 
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IV.2. Anticoagulant properties of the endothelium during the coagulation start 
 A better understanding of the blood coagulation system is of great importance for 
elucidating the pathogenesis of a large variety of diseases, in which the prime cause is the clot 
formation or the absence of it (e.g. arterial and venous thrombosis, hemophilia). Blood 
coagulation is a complex process, ultimately resulting in the formation of fibrin. Several 
molecules are involved as positive and negative regulators of the fibrin generation, 
modulating its velocity and intensity. Currently, TFPI-1 is believed to be the main inhibitor of 
the initiation of coagulation. The microvascular endothelium is the major cell type of the 
human organism that synthesizes TFPI-1. Hence, this cell type might be considered as the 
main anticoagulant unit in the human body. Indeed, any dysfunction in TFPI synthesis in 
embryonic development or in the adult organism results in severe coagulation abnormalities 
(Huang et al. 1997; Mestrick et al. 2001). TFPI is distributed in three pools in vivo; ~80-85% 
is associated with the endothelial surface, representing a strong anticoagulant surface in the 
vessel wall. ~10% circulates in plasma in association with lipoproteins, a truncated form of 
the protein that has reduced inhibitory capacity. ~10% is found in platelets, being a storage 
pool for the protein originally synthesized in the megakaryocytes. In our lab, a model of 
intravascular coagulation has been developed (Engelmann et al. 2003), suggesting that the 
TFPI originating from the activated platelets might be degraded by serine proteases such as 
HNE and Cathepsin G which are known to be exposed on the surface of the neutrophils (Fig. 
4-3). Thereby, neutrophils might be able to regulate the coagulation start in complexes with 
activated platelets. 
  
Figure 4-3. Initiation of intravascular coagulation as promoted by platelet-neutrophil interactions. 
         (From Engelmann et al. 2003) 
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IV.2.1. The role of the platelet-neutrophil system in the initiation of the coagulation 
 
 Neutrophils are the major component of the acute inflammatory response and their 
local activation leads to the release of the serine protease HNE. In term, HNE can 
proteolytically inactivate several inhibitors of the coagulation process including antithrombin 
III, heparin cofactor II and TFPI. It recognizes similar protein motifs in all of them (Val-|-Xaa 
> Ala-|-Xaa). The degradation of these inhibitors may result in local progression of the 
coagulation at the site of inflammation (Jochum et al. 1981, Jordan et al. 1989, Higuchi et al. 
1992). Platelets are a significant source of TFPI, and ample work has shown that activated 
platelets form conjugates with neutrophils under a variety of different conditions (Palabrica et 
al 1992). The interactions are supported by the leukocyte adhesion receptors PSGL-1 and 
CD11/CD18, as well as by P-selectin and ICAMs from the platelet site. We therefore suppose 
a possible link between the stability of platelets secreted TFPI and the serine proteases 
exposed by the neutrophils. Thus, it is feasible that in the local microenvironment of the 
platelet-neutrophil conjugate TFPI is proteolytically degraded by the surface proteases. 
Therefore preventing TFPI from fragmentation could be of prime importance to stabilize the 
anticoagulant function of TFPI for longer time periods. In this work we show that exchanging 
some of the amino acids involved in the proteolytic cleavage of TFPI leads to a delay in the 
blood coagulation in vitro. The TFPI molecule is a trivalent Kunitz-type inhibitor which 
interacts with its K1 domain with factor VIIa, and binds factor Xa with the K2 domain. 
Thereby, a quaternary complex is formed, which blocks the coagulation cascade, because it 
prevents the formation of the activated factor X, capable of activating the sequential substrates 
in the cascade. The linker regions in between the Kunitz domains are the areas that are 
preferentially attacked by most of the proteases. Exchanging amino acids in the linker areas 
saves the charge balance of the entire protein and prevents conformational changes in the 
Kunitz domains, of importance for the overall functional features of the molecule. The first 
site we exchanged (T87F) was the only one known for HNE (Higuchi et al. 1992). The 
substitution of the nucleophilic threonine by the aromatic phenylalanine delayed the 
fragmentation of the molecule, when compared to the native TFPI under the same conditions 
of limited proteolytic digestion with HNE. In the consequential functional experiments we 
observed that in suspensions of isolated platelets and neutrophils as well as in total human 
blood, the activation of coagulation was significantly reduced compared to the effect seen 
with the wild type TFPI. We assumed that the aromatic phenylalanine had hampered the 
access of HNE to the cleavage site. Because of these first promising results, we decided to 
modulate some other digestion sites for proteases.  
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 Exchanging leucine 21 by alanine (L21A), a common proteolytic site for MMPs and 
especially for MMP-9, improved the resistance of the L21A variant molecule in a limited 
proteolytic assay with MMP-9. However, the inhibiting effect of the L21A/T87F mutant was 
only slightly higher than the effect induced by the T87F variant in the factor Xa formation and 
fibrin generation assays. Since we achieved a delay in the limited proteolytic digestion, this 
indicates that the substitution by its own led to the desired effect, but was of poor functional 
relevance. This suggests that there are proteases which attack TFPI with higher affinity. This 
was confirmed when we substituted leucine in position 89 by alanine (L89A), which is a 
proteolytic site for Cathepsin G. Also this mutation was introduced in the T87F variant. The 
results showed a marked delay in the Cathepsin G mediated degradation of the protein. 
Although Cathepsin G has more than one site for proteolytic digestion of the TFPI (Petersen 
et al. 1992), degradation of the T87F/L89A variant was delayed, compared to the wild type 
TFPI, indicating that the mutated site at position L89A into the molecule was of primary 
relevance for its stability. Moreover, we found that the T87F/L89A double mutant resulted in 
an approx two fold reduction of the coagulation activity compared to the wild type TFPI. 
Indeed, this mutant exhibited the strongest inhibition effect of all variants investigated. The 
exchange of L89A in the vicinity of the already mutated T87F may explain the peculiar 
stability of the double mutated TFPI molecule. Concentrating mutated sites outside of the 
Kunitz domains does not interfere with the functionality of the molecule as coagulation 
inhibitor, but in the same time prevents fragmentation, the main reason for the deactivation of 
TFPI. The protease-resistant type of recombinant TFPI investigated may have beneficial 
antithrombotic effect. This may be of relevance under inflammatory conditions, in which the 
most abundant serine proteases such as HNE, Cathepsin G and MMP-9 are secreted by the 
activated neutrophils at the site of injury. On the other hand, constructing a molecule which is 
exclusively modified at many sites of proteolytic cleavage could not be a solution; such a type 
of recombinant protein may lead to severe immune reactions and other complications. We 
thus show that it is possible to modify the structure of TFPI in a way that the function of the 
Kunitz domains remains unchanged, while the stability is largely improved compared to the 




 Mature endothelial cells are terminally differentiated cells with a low proliferative 
potential and their capacity to substitute damaged endothelium is limited. Accumulating 
evidence in the last years indicates that mammalian organisms contain a unique subtype of 
circulating, bone marrow-derived cells with properties similar to those of embryonal 
angioblasts. These cells were called endothelial progenitor cells (EPCs). In the present work, 
we have studied the role of B-Raf and C-Raf, two members of a central intracellular signalling 
pathway, for the proliferation and differentiation of mouse embryonic EPCs. A further 
purpose of the study was to evaluate the anticoagulant properties of the mature endothelium 
and in particular the role of Tissue factor pathway inhibitor (TFPI).  
 We prepared gene constructs allowing us to activate or inhibit the downstream 
signalling of B-Raf and C-Raf, and on the other side we have used RNA interference to knock 
down these proteins. We found that both B-Raf and C-Raf are engaged in the proliferation of 
the eEPCs. However, B-Raf is mostly responsible for the differentiation, and cAMP is 
activating the differentiation through B-Raf, but not through C-Raf.  
 To delineate the participation of the endothelium in coagulation, the role of native 
TFPI and its mutated forms in intravascular fibrin formation was analyzed. Particular 
attention was given to TFPI mutants being resistant towards cleavage by leukocyte proteases 
that might inactivate TFPI under physiological and pathophysiological conditions. The novel 
insights on the differentiation and proliferation of the endothelial progenitor cells obtained in 
the present work, may give us the opportunity to regulate their functionality in certain cases, 






 Reife Endothelzellen sind bereits fertig differenzierte Zellen mit einem niedrigen 
Proliferationspotential, die  nur begrenzt dazu in der Lage sind, beschädigtes Endothel zu 
ersetzen. In den letzten Jahren stellte sich jedoch heraus, dass der Säugetierorganismus über 
eine Subgruppe von im Blut zirkulierenden, aus dem Knochenmark stammenden Zellen 
verfügt, die den embryonalen Angioblasten ähneln und ein sehr hohes Differenzierungs-
potential besitzen. Diese Zellen werden als „Endotheliale Progenitor Zellen“ (EPZs) 
bezeichnet. In der vorliegenden Arbeit untersuchten wir einen für das Wachstum von Zellen 
wichtigen Signaltransduktionsweg in embryonalen endothelialen Maus-Progenitorzellen. 
Dabei interessierten uns insbesondere die beiden Signaltransduktionsproteine B-Raf und C-
Raf und ihre Bedeutung für die Proliferation und Differenzierung der Zellen. Um mehr über 
ihre Funktion zu erfahren, wurden Domänen der Proteine überexprimiert oder die Synthese 
der Proteine unterdrückt. 
 Wir stellten Genkonstrukte her, die den Signalweg über B-Raf und C-Raf flexibel 
aktivieren oder unterbrechen und nutzten die Methoden der RNA-Interferenz um die  
Expression der Proteine zu inhibieren. Wir fanden, dass beide Proteine, B-Raf und C-Raf, 
eine wichtige Rolle bei der Proliferation spielen, wobei C-Raf eine herausragendere Rolle 
zukommt. B-Raf hingegen erwies sich als wichtiger für die Diffenzierung der EPZs. Dies 
bedeutet, dass cAMP die Differenzierung der Zellen durch B-Raf fördert, nicht aber durch C-
Raf. 
Außerdem untersuchten wir die antikoagulatorische Wirkung des reifen Endothels und 
dabei insbesonders den Einfluss des antikoagulatorischen Proteins „Tissue factor pathway 
inhibitor“(TFPI). Um die Rolle des Endothels bei der intravaskulären Gerinnung näher zu 
erforschen, wurde die Funktion von nativem TFPI und seiner Mutanten bei der intra-
vaskulären Bildung von Fibrin analysiert. Eine TFPI Mutante (T87F/L89A), die resistent 
gegenüber der Spaltung und damit Inaktivierung durch leukozytäre Elastase und Cathepsin G, 
erwies sich als besonders effizienter Inhibitor des Gerinnungsstartes.  
 Die in der vorliegenden Arbeit gewonnenen Erkenntnisse zur Differenzierung, 
Proliferation und antikoagulatorische Wirksamkeit endothelialer Proteine könnten die Basis 
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